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Herein we describe the synthesis and properties of substituted phenylaminopyrrolo[1,2-a]quinoxaline-
carboxylic acid derivatives as a novel class of potent inhibitors of the human protein kinase CK2. A set of
15 compounds was designed and synthesized using convenient and straightforward synthesis protocols.
The compounds were tested for inhibition of human protein kinase CK2, which is a potential drug target
for many diseases including inﬂammatory disorders and cancer. New inhibitors with IC50 in the micro-
and sub-micromolar range were identiﬁed. The most promising compound, the 4-[(3-chlorophenyl)
amino]pyrrolo[1,2-a]quinoxaline-3-carboxylic acid 1c inhibited human CK2 with an IC50 of 49 nM. Our
ﬁndings indicate that pyrrolo[1,2-a]quinoxalines are a promising starting scaffold for further develop-
ment and optimization of human protein kinase CK2 inhibitors.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
Protein kinase CK2, formerly known as Casein Kinase 2, is a
ubiquitous eukaryotic serine/threonine protein kinase. CK2 is a
highly pleiotropic enzyme which catalyzes the transfer of terminal
phosphate from ATP or GTP to various proteins implicated in awide
variety of cell functions. The catalytic subunits of CK2 (alpha and/or
alpha0) are constitutively active either alone or in combinationwith
the regulatory beta-subunits to give a heterotetrameric protein. A
third isoform of the catalytic subunit, designated CK2a00, was
discovered more recently [1] and only very limited information isalen, Pharmacochimie, FRE
52; fax: þ33 5 57 57 13 52.
illon).
son SAS. All rights reserved.available. Since its discovery in 1954 by Burnett and Kennedy [2],
the activity of CK2 in physiological and pathological processes has
been largely studied [3e5], particularly in cell proliferation and
apoptosis. Overexpression of CK2 creates a favorable environment
for tumor development. For example CK2 is involved (i) to promote
abnormal pro-survival signals, (ii) to support neovascularization,
(iii) to potentiate MDR phenotypes and (iv) to upregulate DNA
repair. To resume the impact of CK2 on cancer development, recent
works demonstrated that CK2 regulates multiple oncogenic path-
ways such as EGFR pathways (JAK/STAT, MAPK.), Cdc37/HSP90
pathway, Akt pathway (PTEN, PI3K.) [6,7]. Because of its pro-
survival functions and its structural features, a considerable
amount of additional works have been devoted to know its
druggability [8]. CK2 has now emerged as a relevant therapeutic
target for the treatment of cancer (e.g. prostate, mammary gland,
J. Guillon et al. / European Journal of Medicinal Chemistry 65 (2013) 205e222206lung, kidney, hematologic malignancies) [9]. Indeed, diverse stra-
tegies are developed to target CK2 [10], and to synthesize highly
speciﬁc, selective and cell-permeable inhibitors. Most of them are
directed toward the ATP binding site, and belong to (i) coumarins
(ellagic acid), (ii) polyhalogenated benzimidazoles (TBB), (iii) an-
thraquinones (emodin), (iv) pyrazolotriazines, (v) indoloquinazo-
lines (IQA) and naphthyridines and related (CX-4945, CX-5011)
(Fig. 1) [11]. Pre-clinically, CX-4945 demonstrated single agent
potency in suppressing xenograft tumor growth. The studies in BT-
474 breast cancer and BxPC-3 pancreatic xenografts showed robust
antitumor activity including partial and complete regression of
CX4945. These promising results in safety, pharmacokinetics and
efﬁcacy studies led to the clinical evaluation of CX-4945 [12].
The pyrrolo[1,2-a]quinoxaline heterocyclic framework consti-
tutes the basis of an important class of compounds possessing
interesting biological activities. These compounds have been re-
ported to serve as key intermediates for the assembly of several
heterocycles including antipsychotic agent [13], anti-HIV agent
[14], adenosine A3 receptor modulator [15], antiparasitic agents
[16e20], and antitumor agents [21,22]. In this last ﬁeld, the dis-
covery and development of novel therapeutic agents are one of the
most important goals in medicinal chemistry.
Recently, we have designed and developed a series of new
interesting antiproliferative substituted pyrrolo[1,2-a]quinoxalines
[23e25]. Thus, taking into account our experience in the ﬁeld of the
synthesis of new bioactive heterocyclic compounds based on our
pyrrolo[1,2-a]quinoxaline heterocyclic core [16e20,23e25], we
used the pyrrolo[1,2-a]quinoxaline moiety as a template for the
design of new isosteres of the CK2 inhibitors CX-4945 and CX-5011
in which the pyrrolo[1,2-a]quinoxaline nucleus is substituted in
different positions by a carboxylic acid function and a 3-substituted
aniline in comparisonwith the reference compounds (Fig. 2). The 3-
chloroaniline and 3-ethynylaniline motifs were also conserved in
our subsequent molecules in analogy with these reference de-
rivatives CX-4945 and CX-5011. Our new synthesized compounds
were then tested for inhibition of human protein kinase CK2.
The antiproliferative proﬁle of themost potent CK2 inhibitors 1was
then evaluated in vitro against a panel of four leukemic cell lines:
U937, K562, Jurkat and MV-4-11. Moreover, to determine their
respective cytotoxicity, the new pyrrolo[1,2-a]quinoxaline de-
rivatives were tested on activated human peripheral blood mono-
nuclear cells. Finally, a preliminary molecular modeling study wasO
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Fig. 1. Structure of ellagic acid, emodin, TBB, IQA, pycarried out to enlighten the mechanism of action implicating
binding of pyrroloquinoxalines to the ATP-binding CK2 pocket
by using X-ray crystal structure results obtained for compound
CX-4945.
2. Chemistry
The synthesis of the (3-substituted-phenyl)aminopyrrolo[1,2-a]
quinoxaline derivatives 1aen was accomplished from commer-
cially available 3-methyl-2-quinoxalinol, from various substituted
1H-pyrrole-2-carboxylic acid alkyl esters, or from various 2-
nitroanilines via their respective lactames 2aef (Schemes 1e4).
The lactame 2a was prepared in two steps by treatment of
commercially available 3-methyl-2-quinoxalinol with phosphorus
oxychloride leading to the chloro derivative 3 following by conden-
sationwith ethyl bromopyruvate in dry ethanol (Scheme 1) [24]. The
preparation of the N-aryl pyrrole 4 was obtained by nucleophilic
substitution of the diethyl pyrrole-2,3-dicarboxylate 5, previously
prepared according to themethod of Röder et al. [26], with 2-ﬂuoro-
nitrobenzene using cesium carbonate as the base in reﬂuxing DMF
solution (Scheme 1) [24,25]. Reduction of the nitro moiety of 4with
iron in hot glacial acetic acid produced the spontaneous ring closure
onto the ester to afford the desired tricyclic pyrrolo[1,2-a]quinoxa-
line2b through a one-pot reductionecyclization step [24,25]. Similar
substitution of commercially the methyl pyrrole-2-carboxylate with
various ethylﬂuoro-nitrobenzenecarboxylate led to themethyl 1-(4-
or 5-ethoxycarbonyl-2-nitrophenyl)pyrrole-2-carboxylates 6a,b.
Reﬂuxing compounds 6a,b in acetic acid with iron powder also gave
lactames 2c,d. The synthesis of lactame 2e was achieved from 2-
amino-3-nitrobenzoic acid according to two pathways. First,
reﬂuxing 2-amino-3-nitrobenzoic acid in thionyl chloride gave the
corresponding acid chloride, which was treated with ethanol to give
ester 7 in 85% yield [27,28]. The ClausoneKaas reaction of 7with 2,5-
dimethoxytetrahydrofuran (DMTHF) in acetic acid gave the pyrrolic
derivative 8 in 64% yield. The second pathway involved at ﬁrst the
preparation of the 3-nitro-2-pyrrol-1-ylbenzoic acid 9 according to
the ClausoneKaas reaction. This acid 9was then esteriﬁed by treat-
ment with thionyl chloride in ethanol leading to ester 8 [29]. The
resulting 1-(2-nitrophenyl)pyrrole ester intermediate 8 was subse-
quently reduced into the attempted 1-(2-aminophenyl)pyrrole ester
10 using a sodiumborohydrideecopper(II) sulfate in ethanol at room
temperature according to the conditions described by Yoo andCH3
N
N
NHBr
Br
Br
Br
TBB
N
NH
O
OH
O
IQA
NH
Cl
N
N NH
C
HOOC
N
N
CH
CX-5011
razolotriazine derivative, CX-4945 and CX-5011.
compounds 1a-d compounds 1k,l
R = -Cl,
N
N NH
R
COOH
compounds 1e-j
N
N NH
R
HOOC
C CH
N
N COOHNHR
compounds 1m,n
N
N NH
R
HOOC
N
N
N
Pyrrolo[1,2-a]quinoxaline
1 2
3
4
56
7
8
9
Fig. 2. General structures of new synthesized pyrrolo[1,2-a]quinoxaline derivatives 1aen.
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in reducing our aromatic nitro groupswith excellent yield (90%). The
reaction of 10with triphosgene in toluene gave the lactame 2e [16].
These lactames 2aee were subsequently chlorodehydroxylated
with phosphorous oxychloride, leading to the 4-chloropyrrolo[1,2-
a]quinoxalines 11aee (Scheme 2). These 4-chloropyrrolo[1,2-a]
quinoxaline derivatives 11aee underwent nucleophilic attack by
the 3-chloro or 3-ethynylanilines in reﬂuxing dimethylformamide
to give the 4-anilinopyrrolo[1,2-a]quinoxalines 12aej [31]. The 4-
anilinopyrrolo[1,2-a]quinoxalines 12a/c/e/g/i were also prepared
in quite good yields (68e85%) by a direct BuchwaldeHartwig cross-
coupling reaction of 4-chloropyrroloquinoxalines 11aee with 3-
chloroaniline using catalytic amounts of Pd(OAc)2 and BINAP, and
Cs2CO3 as a base [32]. The desired acids 1aej were obtained by
alkaline hydrolysis of the parent esters 12aej in good yields. The 3D
spatial determination of 1f was established by X-ray crystallog-
raphy [33], and conﬁrmed the structure in the solid state as
anticipated on the basis of IR and 1H NMR data (Fig. 3).
The 7-anilinopyrroloquinoxaline-4-carboxylic acids 1k,l were
synthesized in six or seven steps from commercially available 4-
bromo-2-nitroaniline (Scheme 3). Preparation of 1-(4-bromo-2-nit
rophenyl)pyrrole 13was performed according to the ClausoneKaas
reaction runned under micro-waves irradiation starting from 4-
bromo-2-nitroaniline and 2,5-dimethoxytetrahedrofuran in acetic
acid. The resulting phenylpyrrole 13 intermediate was subse-
quently reduced using a NaBH4eCuSO4 treatment into the
attempted 1-(2-amino-4-bromophenyl)pyrrole 14 [18]. Addition of
14 to ethyl chlorooxoacetate in the presence of triethylamineprovided the ester 15 [34,35]. The ethyl 7-bromopyrrolo[1,2-a]
quinoxaline-4-carboxylate 16 was then prepared by cyclization of
the amido-ester 15 in reﬂuxing phosphorus oxychloride [36]. The
3D spatial structure of ethyl 7-bromopyrrolo[1,2-a]quinoxaline-4-
carboxylate 16 was established by X-ray crystallography [33] and
conﬁrmed the structure (Fig. 4).
Then the ethyl 7-anilinopyrrolo[1,2-a]quinoxaline-4-
carboxylates 12k,l were synthesized via the Buchwald palladium-
catalyzed cross-coupling reaction of 3-chloroaniline or 3-(trime-
thylsilylethynyl)aniline [37,38] with 16 in the presence of BINAP
and cesium carbonate (Scheme 3). The deprotection of the acety-
lene moiety of compound 12l by tetrabutylammonium ﬂuoride
(TBAF) led to anilinopyrrolo[1,2-a]quinoxaline 17 [39,40]. The
palladium-catalyzed cross-coupling reaction of unprotected 3-
ethynylaniline with 16 directly gave the Sonogashira side product
18 (Scheme 4). The hydrolysis of the ester function of derivatives
12k,17 and 18 in basic conditions gave the pyrroloquinoxalines 1k,l
and 19, respectively.
The synthesis of the 4-anilinopyrrolo[1,2-a]quinoxaline-7-
carboxylic acids 1m,n, substituted in position 2 by a pyridine
moiety, was depicted in Scheme 5. The methyl 4-bromopyrrole
carboxylate 20 was prepared by regioselective bromination of
methyl pyrrole-2-carboxylate [24]. This bromopyrrole ester 20was
then protected as the corresponding tert-butyl carbamate to afford
21 in nearly quantitative yield. The role of the Boc group is not to
protect nitrogen but to reduce the electron density of the pyrrole to
avoid extensive dehalogenation. Coupling Boc-protected 21 with
3-pyridylboronic acid under SuzukieMiyaura cross-coupling
i ii
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Scheme 3. Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives 1k,l; Reagents and conditions: (i) 2,5-diMeOTHF, AcOH, D; (ii) CuSO4/NaBH4, EtOH, 0 C; (iii) CleCOeCOOC2H5,
TEA, THF, RT; (iv) POCl3, D; (v) 3-substituted aniline, Pd(OAc)2, Cs2CO3, BINAP, toluene, D; (vi) 1) NaOH, MeOH/H2O, D; 2) HCl aq. (1 M), H2O; (vii) Bu4NF/THF (1 M), THF, 5 C.
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carboxylic acid methyl ester 22 after deprotection of the NH using a
triﬂuoroacetic acid solution. An X-ray single crystal analysis was
also performed on pyrrole 22 in order to conﬁrm the structure
(Fig. 5) [33]. The preparation of N-aryl pyrrole 23 were obtained by
nucleophilic substitution of the methyl 4-(3-pyridyl)pyrrole-2-
carboxylate 22 with ethyl 4-ﬂuoro-3-nitrobenzenecarboxylate us-
ing cesium carbonate in reﬂuxing DMF solution (Scheme 5).
Reduction of the nitro moiety with iron in hot acetic acid afforded
the desired lactame 2f. The lactame 2f was subsequently chlor-
odehydroxylated with phosphorous oxychloride, leading to the 4-
chloroquinoxalines 11f. Nucleophilic displacement of the chlorine
by various substituted anilines in 11f and ester hydrolysis provided
carboxylates 12m,n and acids 1m,n.iN
N COOC2H5Br
18
NH2
16
NHC
HC
Scheme 4. Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives 18 and 19; Reagents an
MeOH/H2O, D; 2) HCl aq. (1 M), H2O.3. Biological activity
3.1. Inhibition of human CK2 holoenzyme
These new synthesized pyrrolo[1,2-a]quinoxaline-carboxylic
acid derivatives were tested for their inhibitory activity toward
human CK2 holoenzyme (Table 1). The synthetic peptide
RRRDDDSDDD was used as the substrate, which is reported to be
most efﬁciently phosphorylated by CK2. The purity of the CK2
holoenzyme was superior to 99% (Fig. 6) [41]. For initial testing,
inhibition was determined relative to the controls at inhibitor
concentrations of 10 mM in DMSO as the solvent. Final concentra-
tion of DMSO never exceeded 1% of the entire reaction volume. The
reaction with pure solvent without inhibitor was used as negativeN
N COOC2H5
ii
19
N
N COOH
NH2
N
N COOC2H5
17
d conditions: (i) 3-ethynylaniline, Pd(OAc)2, Cs2CO3, BINAP, toluene, D; (ii) 1) NaOH,
Fig. 3. The ORTEP drawing of pyrrolo[1,2-a]quinoxaline 1f with thermal ellipsoids at
30% level.
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as positive control and set to 100% inhibition. Compounds with
more than 50% inhibition at a concentration of 10 mM were sub-
jected to an IC50 determination. For this purpose, inhibition was
measured at ﬁnal concentrations ranging from 0.01 to 30 mM in
appropriate intervals. IC50 were calculated from the resulting
doseeresponse curves. Each value was determined at least in
triplicate in independent experiments [42].
From the 15 synthesized pyrrolo[1,2-a]quinoxalines, we found
thirteen potent compounds with an inhibition of more than 50% at
a concentration of 10 mM (1aeh,1ken and 19). Nine of them (1ceh,
1k,l and 1n) revealed IC50 in the sub-micromolar range (from 0.049
to 0.982 mM).
Among compounds 1eej, which were bearing the 3-substituted
aniline in position 4 of the heterocycle and the carboxylic acid
function into the benzene of the quinoxaline moiety, the pyrrolo
[1,2-a]quinoxalines 1e and 1f exhibited the best inhibitory activity
toward CK2 (IC50 ¼ 0.118 and 0.078 mM, respectively). Comparison
of derivatives 1g,h and 1i,jwith 1e,f indicated that the presence of a
carboxylic acid function at C8 position or C9 position yielded
signiﬁcantly less potent inhibitors of CK2, showing that the car-
boxylic acid group at C7 position was optimal in analogy with the
reference drug CX-4945. Moreover, replacement of the 3-
chloroaniline by a 3-ethynylaniline did not lead to signiﬁcant
modiﬁcation in the inhibition of CK2 (IC50 ¼ 0.120 mM for 1e versus
0.080 mM for 1f, and IC50 ¼ 0.834 mM for both 1g and 1h).Fig. 4. The ORTEP drawing of pyrrolo[1,2-a]quinoxaline 16 with thermal ellipsoids at
30% level.Moreover, in terms of structureeactivity relationships discus-
sion, it could be also noticed that the IC50 values of compound 1a
and 1b bearing the carboxylic acid group on the pyrrole moiety, i.e.
at position 2 of the heterocyclic skeleton and the 3-substituted
aniline in position 4 (IC50 ¼ 4.28 and 1.89 mM), were found 35
and 24 times lower than those of their 7-substituted analogs 1e,f.
Surprisingly, molecules 1c and 1d, in which the carboxylic acid was
moved to the pyrrolic adjacent carbon, were found to be much
more active in their CK2 inhibitory activity, showing that its posi-
tion on C3 was necessary for potent inhibition. The most promising
compound, the 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxa-
line-3-carboxylic acid 1c inhibited human CK2 with an IC50 of
49 nM. Substitution of the 3-chloroaniline by a 3-ethynylaniline in
compound 1d led to a small decrease in the inhibitory activity
(IC50 ¼ 134 nM).
The transposition of the 3-substituted aniline and the carboxylic
acid from their respective position 4 and 7 in compounds 1e,f to
position 7 and 4 (compounds 1k,l) induced a strong decrease in the
inhibitory activity of CK2 (IC50 0.982 mM for 1k compared with
0.118 mM for 1e; and IC50 0.850 mM for 1l compared with 0.078 mM
for 1f).
In analogy with the reference compound CX-4945, we next
introduced a pyridine into the tricyclic pyrrolo[1,2-a]quinoxaline
core with the objective to add a hydrogen bond acceptor. In the
hinge region, it was noticed a hydrogen bonding interaction be-
tween the pyrido moiety of CX-4945 and the NH of Val116. How-
ever, incorporation of a 3-pyridyl moiety in position 2 of the
pyrroloquinoxaline scaffold (compounds 1e,f) leading to com-
pounds 1m,n induced a 10-fold lower CK2 inhibitory activity, with
IC50 from 0.89 (compound 1n) to 1.57 mM (compound 1m).
From a SAR point of view, these preliminary biological results on
the inhibitory activity toward human CK2 holoenzyme revealed the
importance of the substitution at the C-4 position of the pyrrolo-
quinoxaline scaffold by a 3-substituted aniline, and also revealed
the need of a carboxylic acid functionality on position 3 of the
pyrrole ring. However, in a general way, it could also be noticed that
the nature of the substitution at position 3 in the aniline moiety
was less detrimental than the position of the carboxylic acid
function for the CK2 inhibitory activity of the pyrroloquinoxaline
derivatives 1.
3.2. Antiproliferative effect
The antiproliferative proﬁle of the most promising CK2 in-
hibitors 1 (compounds 1aeh and 1k) at increasing concentrations
(0, 1, 5, 10, 20 and 50 mM) was then evaluated in MTS assay for their
in vitro antiproliferative activity against four human leukemic cell
lines (U937, K562, Jurkat andMV-4-11). Compound CX-4945, which
showed strong CK2 inhibition, was applied as a referential cytotoxic
agent with potent antiproliferative activity against our cell lines.
The results of the antiproliferative activity studies are summarized
in Table 2.
On K562 cell line, all the tested pyrroloquinoxalines 1 were
found to be inactive (CC50 > 50 mM), with the exception of 1c that
presented very moderate antiproliferative activity with a CC50 of
42 mM, while CX-4945 presented a CC50 of 7 mM.
Among compounds 1aeh and 1k, the derivatives 1c and 1k
exhibited a low antiproliferative activity on the growth of U937
monocytic cell line (CC50 values of 47.7 and 39.2 mM, respectively).
On this U937 cell line, reference CX-4945 showed a CC50 of 4.2 mM.
Against the Jurkat T-lymphoblastic cell line, we also observed
moderate antiproliferative activities for compounds 1b and 1k
which presented CC50 of 41 and 31.4 mM, respectively. These anti-
proliferative activities were found 10-fold lower than the one of CX-
4945 (CC50 ¼ 4.5 mM).
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compounds 1e,f were active at a 20 mM concentration, whereas
their structural analog 1k in which the aniline moiety and the
carboxylic acid function were inverted between the 4 and 7 posi-
tions of the pyrroloquinoxaline skeletonwas found twice less active
(CC50 ¼ 47 mM). For compound CX-4945, a CC50 of 3 mM was
observed on MV-4-11, 7-fold lower than the CC50s of pyrroloqui-
noxalines 1e,f.
3.3. Cytotoxicity
The CK2 inhibitor compounds 1aeh and 1k were tested on
activated (PBMNC þ PHA) human peripheral blood mononuclear
cells to evaluate their respective cytotoxicity on normal cells
(Table 2). As expected, all the tested pyrrolo[1,2-a]quinoxalines 1
presented a CC50 superior to 50 mM against lymphocytes. Com-
pound CX-4945 exhibited a CC50 of 50 mM. These preliminary re-
sults were used to determine their respective range of toxic
concentration.
Indexes of selectivity (IS) were deﬁned as the ratio of the CC50
value on the human mononuclear cells to the CC50 value on the
K562, U937, Jurkat and MV-4-11 lines. Compounds that demon-
strated high selectivity (high index of selectivity) should offer a
potential of safer therapy. This led to identify compounds withmoderate index of selectivity >2.5 for compounds 1e,f on the hu-
man leukemic cell line MV-4-11, and 1.6 for compound 1k against
the Jurkat T-lymphoblastic cell line. The reference compound CX-
4945 showed high selectivity with index of selectivity values
noticed between 7.1 and 16.7.
3.4. Lipophilicity and cell permeability
As a previous study on design of indeno[1,2-b]indole derivatives
as CK2 inhibitors [43], predictive ADME parameters were used to
determine their biological proﬁle. Then for an evaluation of the cell
permeability of pyrroloquinoxalines 1aeh and ken, fragment-
based partition coefﬁcients (Clog P) and topological polar surface
areas (TPSA) were calculated by the molinspiration web services
[44]. Compounds 1aeh and ken presented Clog P values between
3.986 for 1b and 5.94 for 1m. TPSA values were noticed between
66.633 and 79.525 A2.
A plot of CK2 inhibitory activity (IC50) versus Clog P values was
presented in Fig. 7, allowing us to classify compounds 1aen in
various subsets. The less lipophilic compounds (1b, 1d, 1l and 1h)
with Clog P values from 3.986 to 4.373 exhibited moderate CK2
inhibitory activities (IC50 ¼ 0.834e1.89 mM) excepted 1d showing
an IC50 of 0.134 mM. The most active pyrroloquinoxalines 1f and 1c
with IC50 of 0.078 and 0.049 mM presented Clog P of 4.373 and
Fig. 5. The ORTEP drawing of ethyl 4-(3-pyridyl)-1H-pyrrole-2-carboxylate 22 with
thermal ellipsoids at 30% level.
Fig. 6. SDS-PAGE of puriﬁed human protein kinase CK2 holoenzyme. 15 mL of puriﬁed
protein solution (0.25 mg/mL) were separated on a 12.5% acrylamide gel and stained
with Coomassie Brilliant Blue G250. At the left, the apparent molecular mass of the
marker proteins (lane 1) is given. Lane 2 shows the puriﬁed human CK2 enzyme
holoenzyme (3.75 mg). The band below the CK2a belongs to the well-known degra-
dation product of the a-subunit CK2a (amino acids 1e335), which is supposed to be
enzymatically active and usually occurs during puriﬁcation [41].
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P values between 4.901 and 5.065 were found to be less active
(IC50 ¼ 0.89e4.28 mM). The reference compound CX-4945
(IC50 ¼ 0.0037 mM) showed a Clog P of 5.136. At Clog P of 5.288,Table 1
CK2 inhibitory activity of new substituted pyrrolo[1,2-a]quinoxaline-carboxylic acid
derivatives.
Compound Inhibition (%)a CK2
IC50 (mM)b
Ellagic acid 95 0.040
Emodin 99 0.580
TBB 99 0.060
CX-4945 100 0.0037
1a 68 4.28
1b 86 1.89
1c 99 0.049
1d 99 0.134
1e 92 0.118
1f 95 0.078
1g 93 0.834
1h 81 0.834
1i 20 n.d.
1j 22 n.d.
1k 99 0.982
1l 95 0.850
1m 75 1.57
1n 89 0.89
19 55 8.25
a Given is the average percent inhibition at 10 mM.
b n.d.: not determined.derivatives 1e and 1g exhibited IC50 of 0.118 and 0.834 mM,
respectively. Compound 1m, showing the most lipophilic value
(Clog P ¼ 5.94), was less active (IC50 ¼ 1.57 mM) on CK2.
Poor absorption and low permeability are predicted for drugs
with Clog P  5 and TPSA  140 A2 [45e47]. Thus, the two most
active compounds 1c and 1f on CK2 showed acceptable lipophilic
properties for cell permeability (Clog P < 5) but their cytotoxic
activity on tested leukemia cell lines was limited (e.g. IC50 ¼ 20 mM
onMV-4-11 for 1f). Furthermore compound 1k (IC50¼ 0.982 mMon
CK2) and CX-4945 had similar Clog P values (5.065 and 5.136,
respectively) and compound 1k only presented slight cytotoxicity
on three cell lines (31.4 < IC50 mM < 47). This suggests that the Clog
P estimates did not seem to ﬁt with our biological results. Further
investigations are ongoing to optimize the correlation of physico-
chemical properties of pyrroloquinoxalines and their biological
potencies.4. Molecular dynamics of CK2 complexes
In order to investigate the molecular basis of the interaction of
the CK2 ATP binding pocket with the 1f and 1c inhibitors, Molec-
ular Dynamics (MD) simulation of CK2/1f and CK2/1c complexesTable 2
In vitro activity of selected CK2 inhibitors compounds 1 on U937, K562, Jurkat and
MV-4-11 cells, and cytotoxicity on human peripheral blood mononuclear cells
PBMNC þ PHA.
CC50 values (mM)a
Compound K562 U937 Jurkat MV-4-11 Cytotoxicity on activated
human peripheral blood
mononuclear cells (PBMNC)
PBMNC þ PHA
CX-4945 7 4.2 4.5 3 50
1a >50 >50 >50 >50 >50
1b >50 >50 41 >50 >50
1c 42 47.7 >50 >50 >50
1d >50 >50 >50 >50 >50
1e >50 >50 >50 20 >50
1f >50 >50 >50 20 >50
1g >50 >50 >50 >50 >50
1h >50 >50 >50 >50 >50
1k >50 39.2 31.4 47 >50
a The CC50 (mM) values correspond to the mean  standard deviation from 3 in-
dependent experiments.
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complex crystal structure (pdb: 3pe1) [48] (Fig. 8a; see
Computational methods) and 1f and 1c optimized geometries, two
protein/inhibitor systems were constructed and 40 ns MD runs
were obtained employing an explicit box of TIP3P water molecules.
Initially, a CK2/CX-4945 MD simulation was carried out as control
trajectory, ﬁnding that both global complex conformation and polar
proteineinhibitor interactions observed in the crystal structure
resulted stable during the simulation time scale. Fig. 8b shows thatFig. 8. Inhibitor binding mode in CK2. X ray structure of the CK2/CX-4945 complex (pdb:
complex (c) and CK2/1c complex (d).the nitrogen atom of the A-ring forms a hydrogen bond with the
backbone nitrogen atom of Val116 (localized at the hinge/aD re-
gion), while on the opposite end of the CX-4945 molecule, the
carboxyl group from the C-ring interacts in a strong polar network
involving the Lys68, Glu81, Asp175 and two water molecules (po-
sitions W1 and W2). The W1 water molecule remained in its
position throughout the 40 ns of the trajectory, while exchanges of
water molecules at the W2 position were observed. We have also
observed that the side chain (D-ring) of the ligand was more ﬂex-
ible than the rest of the molecule, although the global orientation
was conserved. Finally, rotations of the His160 side chain occurred
throughout the 40 ns, continually switching from the up to the
down conformations. Similar MD results related to the CX-4945
binding mode were recently reported by Liu et al. using another
initial structure (pdb: 3nga) [49].
The MD simulation of the CK2/1f binding mode showed very
similar results to those observed in the CX-4945 system (Fig. 8c).
The main difference resides in the lack of polar interactions be-
tween the carbon atoms of the A-ring and the hinge/aD region,
which increases the average distance between this protein region
and the inhibitor (Table 3, distance A). Similar to the CX-4945
system, the carboxyl group of 1f is involved in an extensive polar
interaction network, with a comparable average distance to the
Lys68 (Table 3, distance B), but with a decrease in the average
distance between the Lys68 and the Glu81 residues (Table 3, dis-
tance C). Moreover, the involvement of the W1 and W2 water
molecules in the inhibitor binding mode and the dynamic behavior3pe1) (a) and MD representative snapshots of the CK2/CX-4945 complex (b), CK2/1f
Table 3
Average distance (A).
Average distance (A)
CX-4945 1f 1c
A 3.3  0.3 4.7  0.4 5.4  0.7
B 3.3  0.1 3.3  0.2 3.4  0.2
C 3.5  0.2 3.8  0.5 3.4  0.2
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tory control observed with CX-4945. All together these results
suggest a very stable binding mode of the inhibitor 1f, highlighting
how ﬁve-member A-ring inhibitors could be able to interact within
the ATP binding pocket of the CK2 protein.
We also studied the superposition of optimized geometries of 1f
and 1c. Remarkably, when the superposition of both molecules was
made through the central B-ring, but with an opposite orientation
of the heterocyclic system (i.e. with the 1c A-ring sited at the po-
sition of the 1f C-ring, and vice versa), the position of both carboxyl
groups resulted comparable, with a distance of 2.0A between each
other (Fig. 9). Even more the D-rings and their m-substituents ac-
quired a similar orientation. Afterward, in order to carry out the
CK2/1cMD simulation, the inhibitor was introduced within the ATP
binding pocket in two different initial conﬁgurations: the ﬁrst one
with the heterocyclic system orientated as in the 1f system and the
second one with the heterocyclic system in the opposite orienta-
tion. According to the MD results no polar interaction between 1c
and receptor residues was observed when the inhibitor was
introduced in the ﬁrst conﬁguration, resulting in less stable in-
hibitor trajectory (data not shown). In consequence, this conﬁgu-
ration does not seem to be a suitable binding mode of 1c. When the
inhibitor was introduced in the opposite conﬁguration, a tightly
binding mode was established, with the carboxyl group contacting
the Lys68 and forming part of the polar interaction network as in
the CX-4945 and 1f systems (Fig. 8b,c). Indeed, the interaction
between Lys68 and Glu81 residues resulted slightly larger than in
the 1f system (Table 3). On the other hand, the average distance
between the C-ring and the nitrogen backbone atom of Val116
resulted larger in the 1c system than in the 1f system. This is ex-
pected considering the larger steric impedance of a six-member
ring (1c) in comparison with a ﬁve-member ring (1f) orientated
to the hinge/aD. Notably the intramolecular hydrogen bond formed
between the carboxyl group and the nitrogen atom of B-ring
remained stable during the 40 ns time scale of the simulation.
Finally, to compare qualitatively the different contributions to
the binding energy of 1f and 1c to CK2, we calculated the electro-
static energy (ele) and Van der Waals contributions (vdw), the sum
of which gave the total gas phase binding energy. The results
revealed that vdw contribution is 2.7 kcal/mol more favorable inFig. 9. HF/6-31G** optimized geometries of compounds 1f and 1c and their super-
position generated by aligning the central B-ring.the 1f complex while the ele energy is 7.1 kcal/mol more favorable
in the 1c complex. Thus, without considering the solvation and
entropic effects, we found that the binding of 1c to CK2 was
signiﬁcantly stronger than that for 1f. These observations qualita-
tively correlate with the respective experimental IC50 values.
5. Conclusion
In the present report, we showed that substituted (phenyl-
amino)pyrrolo[1,2-a]quinoxaline-carboxylic acid derivatives are a
novel class of potent inhibitors of the human protein kinase CK2. A
set of 15 compounds was prepared and tested for their inhibitory
activity. New inhibitors with IC50 in the micro- and sub-micromolar
range were identiﬁed. The most promising compound, the 4-[(3-
chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-3-carboxylic acid
1c, inhibited human CK2 with an IC50 of 49 nM. Taken together,
these results show that pyrrolo[1,2-a]quinoxalines, such as 1c, are a
promising starting point for the further development and optimi-
zation of potent CK2 inhibitors. Moreover, it would be interesting to
enlarge the biological evaluation of the most active pyrrolo[1,2-a]
quinoxaline derivatives by measuring the inhibition of endogenous
intracellular CK2 activity in leukemic cell lines in comparison with
CX-4945.
6. Experimental
6.1. Chemistry
Commercially reagents were used as received without addi-
tional puriﬁcation. Melting points were determined with an SM-
LUX-POL Leitz hot-stage microscope and are uncorrected. IR
spectra were recorded on an NICOLET 380FT-IR spectrophotometer.
NMR spectra were recorded with tetramethylsilane as an internal
standard using a BRUKER AVANCE 300 spectrometer. Splitting
patterns have been designated as follows: s ¼ singlet; bs ¼ broad
singlet; d ¼ doublet; t ¼ triplet; q ¼ quartet; dd ¼ double doublet;
m ¼ multiplet. Analytical TLC were carried out on 0.25 precoated
silica gel plates (POLYGRAM SIL G/UV254) and visualization of
compounds after UV light irradiation. Silica gel 60 (70e230 mesh)
was used for column chromatography. Elemental analyses were
found within 0.4% of the theoretical values.
6.1.1. Diethyl 1-(2-nitrophenyl)pyrrole-2,3-dicarboxylate (4)
To a solution of diethyl pyrrole-2,3-dicarboxylate 5 (4.83 mmol)
in 15 mL of DMF was added cesium carbonate (5.80 mmol). The
mixture was stirred at room temperature for 10 min, then 1-ﬂuoro-
2-nitrobenzene (7.25 mmol) was reﬂuxed for 1 h 30 min, then was
diluted in AcOEt (50 mL). The organic layer was washed with water
(2  30 mL), then brine (40 mL) and dried over sodium sulfate. The
organic layer was concentrated under vacuo to give a brown oil.
After triturating in Et2O a solid was obtained and ﬁltered off,
washed with Et2O and dried to give the desired product 4. Orange
oil (92%). IR (KBr) 1700 and 1690 (C]O). 1H NMR (CDCl3) d: 8.06
(dd,1H, J¼ 7.80 and 1.80 Hz, H-30), 7.74e7.56 (m, 2H, H-40 and H-50),
7.40 (dd, 1H, J ¼ 7.80 and 1.80 Hz, H-60), 6.83 (d, 1H, J ¼ 3.00 Hz, H-
5), 6.69 (d, 1H, J¼ 3.00 Hz, H-4), 4.32 (q, 2H, J¼ 7.20 Hz, OCH2), 4.10
(q, 2H, J ¼ 7.20 Hz, OCH2), 1.36 (t, 3H, J ¼ 7.20 Hz, CH3), 1.12 (t, 3H,
J ¼ 7.20 Hz, CH3). Anal. Calcd. for C16H16N2O6: C, 57.83; H, 4.85; N,
8.43. Found: C, 57.66; H, 5.03; N, 8.32.
6.1.2. General procedure for methyl 1-(4-ethoxycarbonyl-2-
nitrophenyl)pyrrole-2-carboxylate (6a) and methyl 1-(5-ethoxy-
carbonyl-2-nitrophenyl)pyrrole-2-carboxylate (6b)
To a solution of methyl pyrrole-2-carboxylate (24.6 mmol) in
85 mL of DMF was added cesium carbonate (29.5 mmol).
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4-ﬂuoro-3-nitrobenzoate or ethyl 3-ﬂuoro-4-nitrobenzoate
(7.25 mmol) was added. The reaction mixture was reﬂuxed for
1 h 30min or 4 h (in case of 6b), thenwas diluted in AcOEt (100mL).
The organic layer was washed with water (2  60 mL), then brine
(70 mL) and dried over sodium sulfate. The organic layer was
concentrated under vacuo to give a brown oil. After triturating in
Et2O a solid was obtained and ﬁltered off, washed with Et2O and
dried to give the desired product 6.
6.1.2.1. Methyl 1-(4-ethoxycarbonyl-2-nitrophenyl)pyrrole-2-
carboxylate (6a). Yellow crystals (62%); mp 77 C. IR (KBr) 1712
(C]O). 1H NMR (CDCl3) d: 8.76 (d, 1H, J ¼ 2.00 Hz, H-30), 8.36 (dd,
1H, J ¼ 8.10 and 2.00 Hz, H-50), 7.52 (d, 1H, J ¼ 8.10 Hz, H-60), 7.15
(dd,1H, J¼ 3.95 and 1.65 Hz, H-5), 6.95 (dd,1H, J¼ 2.85 and 1.65 Hz,
H-3), 6.43 (dd, 1H, J ¼ 3.90 and 2.85 Hz, H-4), 4.47 (q, 2H,
J ¼ 7.20 Hz, OCH2), 3.70 (s, 3H, OCH3), 1.45 (t, 3H, J ¼ 7.20 Hz, CH3).
Anal. Calcd. for C15H14N2O6: C, 56.60; H, 4.43; N, 8.80. Found: C,
56.81; H, 4.29; N, 8.96.
6.1.2.2. Methyl 1-(5-ethoxycarbonyl-2-nitrophenyl)pyrrole-2-
carboxylate (6b). Beige crystals (24%); mp 117 C. IR (KBr) 1710
(C]O). 1H NMR (CDCl3) d: 8.26 (dd, 1H, J ¼ 8.40 and 1.80 Hz, H-40),
8.15 (d, 1H, J¼ 8.40 Hz, H-30), 8.09 (d,1H, J¼ 1.80 Hz, H-60), 7.15 (dd,
1H, J ¼ 3.90 and 1.80 Hz, H-3), 6.97 (dd, 1H, J ¼ 2.70 and 1.80 Hz, H-
5), 6.43 (dd, 1H, J ¼ 3.90 and 2.70 Hz, H-4), 4.44 (q, 2H, J ¼ 7.20 Hz,
OCH2), 3.70 (s, 3H, OCH3), 1.43 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd.
for C15H14N2O6: C, 56.60; H, 4.43; N, 8.80. Found: C, 56.52; H, 4.64;
N, 9.10.
6.1.3. Ethyl 2-amino-3-nitrobenzoate (7)
Amixture of 2-amino-3-nitrobenzoic acid (18 mmol) and 50 mL
of thionyl chloride was reﬂuxed for 3 h. The mixture was then
evaporated in vacuo to dryness and ethanol (80mL) was added. The
resulting solutionwas allowed to stir at room temperature for 15 h.
The ethanol was evaporated and water was added. A yellow solid
was collected by ﬁltration, washed with water and dried to give 7.
Yellow crystals (85%); mp 88 C. IR (KBr) 3380 and 3290 (NH2), 1690
(C]O). 1H NMR (CDCl3) d: 8.61 (bs, 2H, NH2), 8.52 (dd, 1H, J ¼ 8.40
and 1.55 Hz, H-6), 8.29 (dd, 1H, J ¼ 8.40 and 1.55 Hz, H-4), 6.67 (t,
1H, J ¼ 8.40 Hz, H-5), 4.40 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.43 (t, 3H,
J ¼ 7.20 Hz, CH3). Anal. Calcd. for C9H10N2O4: C, 51.43; H, 4.80; N,
13.33. Found: C, 51.62; H, 4.87; N, 13.58.
6.1.4. Ethyl 3-nitro-2-pyrrol-1-ylbenzoate (8)
Method A: A mixture of ethyl 2-amino-3-nitrobenzoate 7
(15 mmol) and 2,5-dimethoxytetrahydrofuran (16.6 mmol) in
acetic acid (40 mL) was reﬂuxed for 4 h with vigorous stirring. After
cooling, the reaction mixture was poured into water. The mixture
was then extracted twice with diethyl ether. The organic layer was
dried over magnesium sulfate and evaporated to dryness under
reduced pressure. The crude residue was then puriﬁed by column
chromatography using AcOEt/cyclohexane (3/7, v/v) as eluent to
give 8.Method B: To a solution of 3-nitro-2-pyrrol-1-ylbenzoic acid
9 (24.6 mmol) in 80 mL of ethanol was added thionyl chloride
(27 mmol). The reaction mixture was heated under reﬂux for 2 h.
Ethanol was evaporated under reduced pressure. The residue was
trituratedwith water then extractedwith ethyl acetate. The organic
layer was washed with a saturated aqueous sodium bicarbonate
solution, dried over sodium sulfate, charcoaled and evaporated to
dryness. The crude residue was then puriﬁed by column chroma-
tography using AcOEt/cyclohexane (3/7, v/v) as eluent to give 8.
Yellow oil (method A: 64%; method B: 32%). IR (KBr) 1695 (C]O).
1H NMR (CDCl3) d: 8.02 (dd, 1H, J ¼ 7.80 and 1.50 Hz, H-6), 7.93 (dd,
1H, J¼ 7.80 and 1.50 Hz, H-4), 7.62 (t, 1H, J¼ 7.80 Hz, H-5), 6.72 (dd,2H, J ¼ 2.10 and 2.10 Hz, 2H-a), 6.34 (dd, 2H, J ¼ 2.10 and 2.10 Hz,
2H-b), 4.15 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.12 (t, 3H, J ¼ 7.20 Hz, CH3).
Anal. Calcd. for C13H12N2O4: C, 60.00; H, 4.65; N, 10.76. Found: C,
59.84; H, 4.51; N, 10.92.
6.1.5. 3-Nitro-2-pyrrol-1-ylbenzoic acid (9)
A mixture of 2-amino-3-nitrobenzoic acid (27.5 mmol) and 2,5-
dimethoxytetrahydrofuran (30 mmol) in acetic acid (70 mL) was
reﬂuxed for 1 h with vigourous stirring. After cooling, the reaction
mixture was poured into water. The mixture was then extracted
twice with diethyl ether. The organic layer was dried over sodium
sulfate and evaporated to dryness under reduced pressure. The
crude residue was recrystallized from petroleum ether to give 9.
Brown crystals (89%); mp 148 C. IR (KBr) 3400e2560 (COOH),1695
(C]O). 1H NMR (CDCl3) d: 8.15 (dd, 1H, J ¼ 7.95 and 1.50 Hz, H-6),
7.97 (dd, 1H, J ¼ 7.95 and 1.50 Hz, H-4), 7.65 (t, 1H, J¼ 7.95 Hz, H-5),
6.81 (bs, 1H, COOH), 6.73 (dd, 2H, J ¼ 2.10 and 2.10 Hz, 2H-a), 6.64
(dd, 2H, J ¼ 2.10 and 2.10 Hz, 2H-b). Anal. Calcd. for C11H8N2O4: C,
56.90; H, 3.47; N, 12.06. Found: C, 57.10; H, 3.49; N, 11.84.
6.1.6. Ethyl 3-amino-2-pyrrol-1-ylbenzoate (10)
To a solution of ethyl 3-nitro-2-pyrrol-1-ylbenzoate 8 (8 mmol)
in ethanol (40 mL) was added 6.5 mL of a 2 M aqueous solution of
CuSO4. Sodium borohydride (40 mmol) was added portion-wise at
0 C to the reaction mixture which was then stirred at room tem-
perature for 1 h. The reaction mixture was then diluted with ethyl
acetate and ﬁltered. The organic layer was separated, dried over
Na2SO4 and evaporated to dryness under reduced pressure to give
10. Orange oil (90%). IR (KBr) 3380 and 3290 (NH2), 1695 (C]O). 1H
NMR (CDCl3) d: 7.29e7.21 (m, 2H, H-5 and H-6), 6.93 (dd, 1H,
J ¼ 7.40 and 2.20 Hz, H-4), 6.70 (dd, 2H, J ¼ 2.10 and 2.10 Hz, 2H-a),
6.35 (dd, 2H, J ¼ 2.10 and 2.10 Hz, 2H-b), 4.10 (q, 2H, J ¼ 7.20 Hz,
OCH2), 3.73 (bs, 2H, NH2), 1.11 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd.
for C13H14N2O2: C, 67.81; H, 6.13; N, 12.17. Found: C, 68.03; H, 6.27;
N, 12.30.
6.1.7. General procedure for ethyl 4-oxo-5H-pyrrolo[1,2-a]
quinoxaline-carboxylates (2bed) and ethyl 4-oxo-2-(3-pyridyl)-
5H-pyrrolo[1,2-a]quinoxaline-7-carboxylate (2f)
A suspension of 4 or 6a,b or 23 (12.3 mmol) and iron powder
(49.1 mmol) in 55 mL of acetic acid was heated under reﬂux for 2 h.
The reaction mixture was cooled, suspended in 150 mL of a 1 M
aqueous solution of HCl, agitated, then ﬁltered off, washedwith HCl
1 M (80 mL), water, Et2O and dried to give a ﬂuffy white solid.
6.1.7.1. Ethyl 4-oxo-5H-pyrrolo[1,2-a]quinoxaline-3-carboxylate
(2b). Beige crystals (57%); mp 225 C. IR (KBr) 3200e2800 (CONH
lactame), 1725 (COO), 1670 (CON). 1H NMR (DMSO-d6) d: 11.46 (s,
1H, NH), 8.25 (d, 1H, J ¼ 2.85 Hz, H-1), 8.12 (d, 1H, J ¼ 8.10 Hz, H-9),
7.35e7.30 (m, 2H, H-6 and H-8), 7.26e7.21 (m, 1H, H-7), 6.96 (d, 1H,
J ¼ 2.85 Hz, H-2), 4.26 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.30 (t, 3H,
J ¼ 7.20 Hz, CH3). Anal. Calcd. for C14H12N2O3: C, 65.62; H, 4.72; N,
10.93. Found: C, 65.49; H, 4.78; N, 11.04.
6.1.7.2. Ethyl 4-oxo-5H-pyrrolo[1,2-a]quinoxaline-7-carboxylate
(2c). White crystals (92%); mp 251 C. IR (KBr) 3200e2800 (CONH
lactame),1710 (COO),1650 (CON). 1HNMR (DMSO-d6) d: 11.42 (s,1H,
NH), 8.25 (d,1H, J¼ 1.95Hz, H-6), 8.15 (d,1H, J¼ 8.20Hz, H-9), 7.94e
7.92 (m, 1H, H-1), 7.74 (dd, 1H, J ¼ 8.20 and 1.95 Hz, H-8), 7.09e7.07
(m,1H, H-3), 6.76e6.73 (m,1H, H-2), 4.34 (q, 2H, J¼ 7.20 Hz, OCH2),
1.33 (t, 3H, J¼ 7.20 Hz, CH3). Anal. Calcd. for C14H12N2O3: C, 65.62; H,
4.72; N, 10.93. Found: C, 65.74; H, 4.58; N, 11.09.
6.1.7.3. Ethyl 4-oxo-5H-pyrrolo[1,2-a]quinoxaline-8-carboxylate
(2d). Beige crystals (28%); mp >275 C. IR (KBr) 3200e2800
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11.60 (s, 1H, NH), 8.53 (d, 1H, J¼ 1.80 Hz, H-9), 8.38 (dd, 1H, J ¼ 2.90
and 1.90 Hz, H-1), 7.87 (dd, 1H, J ¼ 8.40 and 1.80 Hz, H-7), 7.38 (d,
1H, J ¼ 8.40 Hz, H-6), 7.08 (dd, 1H, J ¼ 3.95 and 1.90 Hz, H-3), 6.71
(dd, 1H, J ¼ 3.95 and 2.90 Hz, H-2) 4.35 (q, 2H, J ¼ 6.90 Hz, OCH2),
1.36 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd. for C14H12N2O3: C, 65.62;
H, 4.72; N, 10.93. Found: C, 65.51; H, 4.80; N, 11.15.
6.1.7.4. Ethyl 4-oxo-2-(3-pyridyl)-5H-pyrrolo[1,2-a]quinoxaline-7-
carboxylate (2f). Beige crystals (92%); mp >270 C. IR (KBr) 3400e
3150 (CONH lactame), 1710 (COO), 1685 (CON). 1H NMR (DMSO-d6)
d: 11.58 (s,1H,NH), 9.34e9.33 (m,1H,H-1), 9.11 (d,1H, J¼1.80Hz, H-
6), 8.76e8.73 (m, 2H, H-60 and H-40), 8.16 (d, 1H, J ¼ 8.40 Hz, H-9),
7.97e7.93 (m, 2H,H-8 andH-20), 7.85 (dd,1H, J¼7.90 and5.00Hz,H-
50), 7.81e7.80 (m,1H, H-3), 4.36 (q, 2H, J¼ 6.90Hz, OCH2),1.35 (t, 3H,
J ¼ 6.90 Hz, CH3). Anal. Calcd. for C19H15N3O3: C, 68.46; H, 4.54; N,
12.61. Found: C, 68.33; H, 4.72; N, 12.78.
6.1.8. Ethyl 4-oxo-5H-pyrrolo[1,2-a]quinoxaline-9-carboxylate (2e)
To a solution of compound 10 (7 mmol) in toluene (30 mL) was
added triphosgene (2.34 mmol). The reaction mixture was reﬂuxed
for 4 h, and nitrogenwas bubbled in to drive off excess of phosgene.
The solution was then set aside for 10 min. The heavy crystalline
precipitate was ﬁltered off and washed with diethyl ether to give
2e. White crystals (75%); mp 243 C. IR (KBr) 3400e3950 (CONH
lactame), 1720 (COO), 1660 (CON). 1H NMR (DMSO-d6) d: 11.52 (s,
1H, NH), 7.47 (dd, 1H, J ¼ 3.00 and 1.20 Hz, H-1), 7.45 (dd, 1H,
J ¼ 7.80 and 1.80 Hz, H-6), 7.37 (t, 1H, J ¼ 7.80 Hz, H-7), 7.30 (dd, 1H,
J ¼ 7.80 and 1.80 Hz, H-8), 7.11 (dd, 1H, J ¼ 3.90 and 1.20 Hz, H-3),
6.70 (dd, 1H, J ¼ 3.90 and 3.00 Hz, H-2), 4.46 (q, 2H, J ¼ 7.10 Hz,
OCH2), 1.33 (t, 3H, J ¼ 7.10 Hz, CH3). Anal. Calcd. for C14H12N2O3: C,
65.62; H, 4.72; N, 10.93. Found: C, 65.83; H, 4.85; N, 11.10.
6.1.9. General procedure for ethyl 4-chloropyrrolo[1,2-a]
quinoxaline-carboxylates (11bee) and ethyl 4-chloro-2-(3-pyridyl)
pyrrolo[1,2-a]quinoxaline-7-carboxylate (11f)
A solution of 5H-pyrrolo[1,2-a]quinoxalin-4-one 2aef (4 mmol)
in POCl3 (8 mL) was reﬂuxed for 2 h. After removing excess of
reactive under vacuum, the residuewas carefully dissolved inwater
at 0 C and the resulting solution was made basic with sodium
carbonate. The precipitate was ﬁltered, dried and recrystallized
from ethyl acetate to give 11.
6.1.9.1. Ethyl 4-chloropyrrolo[1,2-a]quinoxaline-3-carboxylate (11b).
White crystals (89%); mp 100 C. IR (KBr) 1710 (COO). 1H NMR
(CDCl3) d: 7.94 (d,1H, J¼ 2.55 Hz, H-1), 7.92 (d, 1H, J¼ 8.10 Hz, H-9),
7.86 (d, 1H, J¼ 8.10 Hz, H-6), 7.62 (t, 1H, J¼ 8.10 Hz, H-8), 7.52 (t, 1H,
J¼ 8.10Hz, H-7), 7.25 (d,1H, J¼ 2.55Hz, H-2), 4.44 (q, 2H, J¼ 7.20Hz,
OCH2),1.45 (t, 3H, J¼ 7.20 Hz, CH3). Anal. Calcd. for C14H11ClN2O2: C,
61.21; H, 4.04; N, 10.20. Found: C, 61.13; H, 3.82; N, 10.28.
6.1.9.2. Ethyl 4-chloropyrrolo[1,2-a]quinoxaline-7-carboxylate (11c).
White crystals (82%); mp 137 C. IR (KBr) 1715 (COO). 1H NMR
(CDCl3) d: 8.64 (d, 1H, J ¼ 2.00 Hz, H-6), 8.24 (dd, 1H, J ¼ 8.10 and
2.00 Hz, H-8), 8.05e8.04 (m, 1H, H-1), 7.89 (d, 1H, J ¼ 8.10 Hz, H-9),
7.14e7.12 (m, 1H, H-3), 6.99e6.96 (m, 1H, H-2), 4.45 (q, 2H,
J ¼ 7.20 Hz, OCH2), 1.45 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for
C14H11ClN2O2: C, 61.21; H, 4.04; N,10.20. Found: C, 61.34; H, 3.92; N,
10.36.
6.1.9.3. Ethyl 4-chloropyrrolo[1,2-a]quinoxaline-8-carboxylate (11d).
White crystals (80%); mp 161 C. IR (KBr) 1705 (COO). 1H NMR
(CDCl3) d: 8.57 (d, 1H, J ¼ 1.80 Hz, H-9), 8.14e8.11 (m, 1H, H-7), 7.95
(d,1H, J¼ 8.70 Hz, H-6), 7.13 (dd,1H, J¼ 3.90 and 1.90 Hz, H-3), 6.96
(dd, 1H, J ¼ 3.90 and 3.00 Hz, H-2), 4.48 (q, 2H, J ¼ 7.20 Hz, OCH2),1.48 (t, 3H, J¼ 7.20 Hz, CH3). Anal. Calcd. for C14H11ClN2O2: C, 61.21;
H, 4.04; N, 10.20. Found: C, 61.09; H, 3.87; N, 10.32.
6.1.9.4. Ethyl 4-chloropyrrolo[1,2-a]quinoxaline-9-carboxylate (11e).
White crystals (80%); mp 84 C. IR (KBr) 1695 (COO). 1H NMR
(CDCl3) d: 8.02 (dd, 1H, J ¼ 7.80 and 1.50 Hz, H-6), 7.85 (dd, 1H,
J ¼ 3.00 and 1.20 Hz, H-1), 7.69 (dd, 1H, J ¼ 7.80 and 1.50 Hz, H-8),
7.48 (t, 1H, J ¼ 7.80 Hz, H-7), 7.13 (dd, 1H, J ¼ 3.90 and 1.20 Hz, H-3),
6.89 (dd, 1H, J ¼ 3.90 and 3.00 Hz, H-2), 4.55 (q, 2H, J ¼ 6.90 Hz,
OCH2), 1.46 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd. for C14H11ClN2O2:
C, 61.21; H, 4.04; N, 10.20. Found: C, 61.44; H, 4.19; N, 10.15.
6.1.9.5. Ethyl 4-chloro-2-(3-pyridyl)pyrrolo[1,2-a]quinoxaline-7-
carboxylate (11f). White crystals (68%); mp 259 C. IR (KBr) 1710
(COO). 1H NMR (DMSO-d6) d: 9.40 (d, 1H, J ¼ 1.20 Hz, H-1), 9.23 (d,
1H, J¼ 1.80 Hz, H-6), 8.61e8.58 (m,1H, H-40), 8.47e8.43 (m, 2H, H-9
and H-60), 8.36 (d, 1H, J ¼ 1.80 Hz, H-20), 8.23 (dd, 1H, J ¼ 8.40 and
1.80 Hz, H-8), 7.78 (d, 1H, J ¼ 1.20 Hz, H-3), 7.65e7.60 (m, 1H, H-50),
4.39 (q, 2H, J ¼ 6.90 Hz, OCH2), 1.38 (t, 3H, J ¼ 6.90 Hz, CH3). Anal.
Calcd. for C19H14ClN3O2: C, 64.87; H, 4.01; N, 11.94. Found: C, 65.03;
H, 4.08; N, 12.14.
6.1.10. General procedure for ethyl 4-[(3-substituted-phenyl)amino]
pyrrolo[1,2-a]quinoxaline-carboxylates 12aej and ethyl 7-[(3-sub-
stituted-phenyl)amino]pyrrolo[1,2-a]quinoxaline-4-carboxylates
12k,l and ethyl 4-[(3-substituted-phenyl)amino]-2-(3-pyridyl)
pyrrolo[1,2-a]quinoxaline-7-carboxylates 12m,n
Method A: Ethyl 4-chloropyrrolo[1,2-a]quinoxaline-carboxylates
11bee or ethyl 4-chloro-2-(3-pyridyl)pyrrolo[1,2-a]quinoxaline-7-
carboxylate (11f) (1.5 mmol), 3-substituted aniline (1.95 mmol),
andDMF (10mL)weremixed andheated at reﬂux for 2h30min. The
reaction mixture was then diluted with ethyl acetate. The organic
layer was washed with water thenwith brine, separated, dried over
Na2SO4 and evaporated to dryness under reduced pressure. The
crude residue was triturated in diethyl ether, ﬁltered and then pu-
riﬁed by column chromatography using AcOEt/cyclohexane (3/7,
v/v) as eluent to give 12aej and 12m,n. Method B: A mixture of 4-
chloropyrrolo[1,2-a]quinoxalines 11a/c/e/g/i/m or 7-bromopyrrolo
[1,2-a]quinoxaline (16) (1 mmol), 3-substituted aniline (1.2 mmol),
Cs2CO3 (1.4 mmol), Pd(OAc)2 (0.05 mmol) and BINAP (0.075 mmol)
in 5 mL of toluene was heated at 100 C for 20 h. The reaction
mixture was allowed to cool to room temperature, diluted with
dichloromethane and ﬁltered through a pad of Celite and the ﬁlter
cake was washed with dichloromethane (3). Concentration and
ﬂash chromatography on silica gel using AcOEt/cyclohexane (3/7,
v/v) as eluent afforded 12a/c/e/g/i/m and 12k,l, respectively.
6.1.10.1. Ethyl 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
2-carboxylate (12a). White crystals (method A: 44%; method B:
51%); mp 183 C. IR (KBr) 3390 (NH), 1690 (COO). 1H NMR (DMSO-
d6) d: 9.45 (s, 1H, NH), 8.93 (d, 1H, J ¼ 1.50 Hz, H-1), 8.35 (d, 1H,
J ¼ 1.80 Hz, H-20), 8.32 (dd, 1H, J ¼ 8.00 and 1.40 Hz, H-9), 8.06 (dd,
1H, J ¼ 8.20 and 1.65 Hz, H-60), 7.88 (d, 1H, J ¼ 1.50 Hz, H-3), 7.64
(dd, 1H, J ¼ 8.00 and 1.40 Hz, H-6), 7.46e7.33 (m, 3H, H-7, H-8 and
H-50), 7.11e7.07 (m,1H, H-40), 4.36 (q, 2H, J¼ 7.20 Hz, OCH2), 1.37 (t,
3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for C20H16ClN3O2: C, 65.67; H,
4.41; N, 11.49. Found: C, 65.78; H, 4.47; N, 11.62.
6.1.10.2. Ethyl 4-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-
2-carboxylate (12b). White crystals (method A: 62%); mp 161 C. IR
(KBr) 3395 (NH), 2105 (C^C), 1685 (COO). 1H NMR (CDCl3) d: 8.37
(s, 1H, NH), 8.05 (d, 1H, J ¼ 1.40 Hz, H-1), 7.91 (dd, 1H, J ¼ 7.90 and
1.50 Hz, H-9), 7.79e7.76 (m, 2H, H-20 and H-60), 7.44e7.32 (m, 3H,
H-6, H-7 and H-8), 7.26e7.22 (m, 2H, H-3 and H-50), 6.93e6.91 (m,
1H, H-40), 4.39 (q, 2H, J ¼ 7.20 Hz, OCH2), 3.11 (s, 1H, C^CH), 1.42 (t,
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N, 11.82. Found: C, 74.50; H, 4.97; N, 11.76.
6.1.10.3. Ethyl 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
3-carboxylate (12c). Pale-yellow crystals (method A: 45%; method
B: 48%); mp 146 C. IR (KBr) 3410 (NH), 1690 (COO). 1H NMR
(DMSO-d6) d: 12.19 (s,1H, NH), 8.49 (d,1H, J¼ 3.30 Hz, H-1), 8.35 (d,
1H, J ¼ 2.10 Hz, H-20), 8.27 (dd, 1H, J ¼ 8.10 and 1.20 Hz, H-9), 7.77e
7.73 (m,1H, H-60), 7.69 (dd, 1H, J¼ 8.10 and 1.20 Hz, H-6), 7.52e7.44
(m, 2H, H-7 and H-8), 7.42 (t, 1H, J ¼ 8.10 Hz, H-50), 7.33 (d, 1H,
J ¼ 3.30 Hz, H-2), 7.14e7.10 (m, 1H, H-40), 4.42 (q, 2H, J ¼ 7.20 Hz,
OCH2), 1.39 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for C20H16ClN3O2:
C, 65.67; H, 4.41; N, 11.49. Found: C, 65.48; H, 4.32; N, 11.53.
6.1.10.4. Ethyl 4-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-
3-carboxylate (12d). Yellow crystals (method A: 52%); mp 122 C. IR
(KBr) 3390 (NH), 2100 (C^C), 1695 (COO). 1H NMR (DMSO-d6) d:
12.07 (s, 1H, NH), 8.44 (d, 1H, J¼ 3.10 Hz, H-1), 8.25e8.17 (m, 2H, H-
20 and H-9), 8.03e8.00 (m, 1H, H-60), 7.70e7.66 (m, 1H, H-6), 7.51e
7.40 (m, 3H, H-50, H-7 and H-8), 7.31 (d, 1H, J ¼ 3.10 Hz, H-2), 7.18e
7.16 (m,1H, H-40), 4.47 (q, 2H, J¼ 6.90 Hz, OCH2), 4.17 (s,1H, C^CH),
1.40 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd. for C22H17N3O2: C, 74.35;
H, 4.82; N, 11.82. Found: C, 74.17; H, 4.65; N, 11.91.
6.1.10.5. Ethyl 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
7-carboxylate (12e). White crystals (method A: 74%; method B:
69%); mp 236 C. IR (KBr) 3375 (NH), 1685 (COO). 1H NMR (DMSO-
d6) d: 9.41 (s, 1H, NH), 8.41 (dd, 1H, J ¼ 3.00 and 1.20 Hz, H-1), 8.27
(d, 1H, J ¼ 1.50 Hz, H-6), 8.23 (d, 1H, J ¼ 8.20 Hz, H-9), 8.13 (d, 1H,
J ¼ 1.80 Hz, H-20), 8.05 (dd, 1H, J ¼ 8.20 and 1.50 Hz, H-8), 7.87 (dd,
1H, J¼ 8.20 and 1.60 Hz, H-60), 7.45 (dd, 1H, J¼ 3.60 and 1.20 Hz, H-
3), 7.41 (t, 1H, J¼ 8.20 Hz, H-50), 7.10 (dd,1H, J¼ 8.20 and 1.80 Hz, H-
40), 6.92 (dd, 1H, J ¼ 3.60 and 3.00 Hz, H-2), 4.37 (q, 2H, J ¼ 7.20 Hz,
OCH2),1.37 (t, 3H, J¼ 7.20 Hz, CH3). Anal. Calcd. for C20H16ClN3O2: C,
65.67; H, 4.41; N, 11.49. Found: C, 65.60; H, 4.54; N, 11.82.
6.1.10.6. Ethyl 4-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-
7-carboxylate (12f). White crystals (method A: 78%); mp 183 C. IR
(KBr) 3380 (NH), 2105 (C^C), 1695 (COO). 1H NMR (DMSO-d6) d:
9.38 (s, 1H, NH), 8.43 (dd, 1H, J¼ 3.00 and 1.20 Hz, H-1), 8.25 (d, 1H,
J ¼ 8.70 Hz, H-9), 8.21e8.18 (m, 2H, H-6 and H-8), 8.13 (d, 1H,
J ¼ 1.80 Hz, H-20), 7.87 (dd, 1H, J ¼ 8.40 and 1.80 Hz, H-60), 7.47 (dd,
1H, J ¼ 3.90 and 1.20 Hz, H-3), 7.42 (t, 1H, J ¼ 8.400 Hz, H-50), 7.17
(dd, 1H, J ¼ 8.40 and 1.80 Hz, H-40), 6.92 (dd, 1H, J ¼ 3.90 and
3.00 Hz, H-2), 4.37 (q, 2H, J ¼ 7.20 Hz, OCH2), 4.02 (s, 1H, C^CH),
1.37 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for C22H17N3O2: C, 74.35;
H, 4.82; N, 11.82. Found: C, 74.21; H, 4.99; N, 12.10.
6.1.10.7. Ethyl 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
8-carboxylate (12g). Beige crystals (method A: 69%; method B:
76%); mp 191 C. IR (KBr) 3400 (NH), 1685 (COO). 1H NMR (DMSO-
d6) d: 9.53 (s, 1H, NH), 8.63 (d, 1H, J ¼ 1.80 Hz, H-9), 8.53 (dd, 1H,
J ¼ 3.00 and 1.20 Hz, H-1), 8.32 (t, 1H, J ¼ 1.90 Hz, H-20), 8.04e8.01
(m, 1H, H-7), 7.91 (dd, 1H, J ¼ 8.20 and 1.60 Hz, H-60), 7.66 (d, 1H,
J¼ 8.40 Hz, H-6), 7.48 (dd, 1H, J¼ 3.90 and 1.20 Hz, H-3), 7.41 (t, 1H,
J ¼ 8.20 Hz, H-50), 7.13e7.10 (m, 1H, H-40), 6.88 (dd, 1H, J ¼ 3.90 and
3.00 Hz, H-2), 4.37 (q, 2H, J ¼ 7.10 Hz, OCH2), 1.38 (t, 3H, J ¼ 7.10 Hz,
CH3). Anal. Calcd. for C20H16ClN3O2: C, 65.67; H, 4.41; N, 11.49.
Found: C, 65.42; H, 4.29; N, 11.53.
6.1.10.8. Ethyl 4-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-
8-carboxylate (12h). Beige crystals (method A: 70%); mp 206 C. IR
(KBr) 3385 (NH), 2100 (C^C), 1685 (COO). 1H NMR (DMSO-d6) d:
9.48 (s, 1H, NH), 8.63e8.61 (m, 1H, H-9), 8.53e8.52 (m, 1H, H-1),
8.24e8.23 (m, 1H, H-20), 8.19e8.13 (m, 1H, H-7), 7.92e7.89 (m, 1H,H-60), 7.66e7.62 (m, 1H, H-6), 7.46e7.38 (m, 2H, H-3 and H-50),
7.20e7.17 (m, 1H, H-40), 6.88e6.86 (m, 1H, H-2), 4.36 (q, 2H,
J ¼ 7.10 Hz, OCH2), 4.23 (s, 1H, C^CH), 1.37 (t, 3H, J ¼ 7.10 Hz, CH3).
Anal. Calcd. for C22H17N3O2: C, 74.35; H, 4.82; N, 11.82. Found: C,
74.46; H, 4.87; N, 12.06.
6.1.10.9. Ethyl 4-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
9-carboxylate (12i). Beige crystals (method A: 75%; method B:
65%); mp 172 C. IR (KBr) 3390 (NH), 1690 (COO). 1H NMR (DMSO-
d6) d: 9.43 (s, 1H, NH), 8.31 (t, 1H, J ¼ 1.60 Hz, H-20), 8.01 (dd, 1H,
J ¼ 7.80 and 1.60 Hz, H-60), 7.79e7.76 (m, 1H, H-6), 7.66 (dd, 1H,
J ¼ 3.00 and 1.20, H-1), 7.48 (dd, 1H, J ¼ 3.90 and 1.20 Hz, H-3),
7.45e7.43 (m, 2H, H-7 and H-8), 7.40 (t, 1H, J ¼ 7.80 Hz, H-50), 7.09
(dd, 1H, J ¼ 7.80 and 1.60 Hz, H-40), 6.88 (dd, 1H, J ¼ 3.90 and
3.00 Hz, H-2), 4.48 (q, 2H, J¼ 7.20 Hz, OCH2), 1.35 (t, 3H, J¼ 7.20 Hz,
CH3). Anal. Calcd. for C20H16ClN3O2: C, 65.67; H, 4.41; N, 11.49.
Found: C, 65.86; H, 4.39; N, 11.64.
6.1.10.10. Ethyl 4-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxa-
line-9-carboxylate (12j). Beige crystals (method A: 79%); mp 141 C.
IR (KBr) 3390 (NH), 2105 (C^C), 1685 (COO). 1H NMR (DMSO-d6) d:
9.34 (s, 1H, NH), 8.21 (t, 1H, J ¼ 1.70 Hz, H-20), 8.15 (d, 1H,
J ¼ 8.00 Hz, H-60), 7.77e7.73 (m, 1H, H-6), 7.65 (dd, 1H, J ¼ 3.00 and
1.20, H-1), 7.48 (dd,1H, J¼ 3.90 and 1.20 Hz, H-3), 7.44e7.40 (m, 2H,
H-7 and H-8), 7.39 (t, 1H, J ¼ 8.00 Hz, H-50), 7.16 (d, 1H, J ¼ 8.00 Hz,
H-40), 6.87 (dd, 1H, J ¼ 3.90 and 3.00 Hz, H-2), 4.98 (q, 2H,
J ¼ 7.20 Hz, OCH2), 4.19 (s, 1H, C^CH), 1.35 (t, 3H, J ¼ 7.20 Hz, CH3).
Anal. Calcd. for C22H17N3O2: C, 74.35; H, 4.82; N, 11.82. Found: C,
74.54; H, 4.98; N, 12.14.
6.1.10.11. Ethyl 7-[(3-chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-
4-carboxylate (12k). Orange crystals (method B: 37%); mp 115 C. IR
(KBr) 3425 (NH), 1725 (COO). 1H NMR (CDCl3) d: 7.98e7.97 (m, 1H,
H-1), 7.85 (d, 1H, J ¼ 1.40 Hz, H-6), 7.83 (d, 1H, J ¼ 8.20 Hz, H-9),
7.53e7.52 (m, 1H, H-3), 7.36 (dd, 1H, J ¼ 8.20 and 1.40 Hz, H-8), 7.21
(t, 1H, J ¼ 8.10 Hz, H-50), 7.11 (t, 1H, J ¼ 1.70 Hz, H-20), 7.03e6.93 (m,
3H, H-40, H-60 and H-2), 5.98 (s, 1H, NH), 4.60 (q, 2H, J ¼ 7.20 Hz,
OCH2), 1.53 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for C20H16ClN3O2:
C, 65.67; H, 4.41; N, 11.49. Found: C, 65.54; H, 4.65; N, 11.57.
6.1.10.12. Ethyl 7-{[3-(2-trimethylsilylethynyl)phenyl]amino}pyrrolo
[1,2-a]quinoxaline-4-carboxylate (12l). Orange crystals (method B:
12%);mp59 C. IR (KBr) 3410 (NH), 2100 (C^C),1720 (COO).1HNMR
(CDCl3) d: 8.01 (dd, 1H, J¼ 2.70 and 1.20 Hz, H-1), 7.89e7.85 (m, 2H,
H-6 and H-9), 7.57 (dd, 1H, J ¼ 3.90 and 1.20 Hz, H-3), 7.29 (dd, 1H,
J ¼ 8.30 and 2.40 Hz, H-8), 7.22 (t, 1H, J ¼ 1.70 Hz, H-20), 7.17 (t, 1H,
J ¼ 7.80 Hz, H-50), 7.10e7.04 (m, 2H, H-40 and H-60), 6.94 (dd, 1H,
J ¼ 3.90 and 2.70 Hz, H-2), 6.11 (s, 1H, NH), 4.58 (q, 2H, J ¼ 7.10 Hz,
OCH2), 1.48 (t, 3H, J¼ 7.10 Hz, CH3). Anal. Calcd. for C25H25N3O2Si: C,
70.23; H, 5.89; N, 9.83. Found: C, 70.39; H, 6.02; N, 10.05.
6.1.10.13. Ethyl 4-[(3-chlorophenyl)amino]-2-(3-pyridyl)pyrrolo[1,2-
a]quinoxaline-7-carboxylate (12m). Beige crystals (method A: 61%;
method B: 67%); mp 234 C. IR (KBr) 3380 (NH), 1710 (COO). 1H
NMR (DMSO-d6) d: 9.44 (s, 1H, NH), 9.03e8.99 (m, 2H, H-1 and H-
6), 8.52e8.50 (m, 1H, H-40), 8.27e8.17 (m, 2H, H-60 and H-9), 8.10e
8.03 (m, 3H, H-200, H-20 and H-8), 7.90e7.84 (m, 2H, H-3 and H-600),
7.52e7.50 (m, 1H, H-50), 7.45e7.39 (m, 1H, H-500), 7.10e7.08 (m, 1H,
H-400), 4.35 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.37 (t, 3H, J ¼ 7.20 Hz, CH3).
Anal. Calcd. for C25H19ClN4O2: C, 67.80; H, 4.32; N, 12.65. Found: C,
67.96; H, 4.44; N, 12.80.
6.1.10.14. Ethyl 4-[(3-ethynylphenyl)amino]-2-(3-pyridyl)pyrrolo
[1,2-a]quinoxaline-7-carboxylate (12n). Beige crystals (method A:
53%); mp 192 C. IR (KBr) 3285 (NH), 2100 (C^C), 1700 (COO). 1H
J. Guillon et al. / European Journal of Medicinal Chemistry 65 (2013) 205e222218NMR (DMSO-d6) d: 9.42 (s, 1H, NH), 9.05e9.04 (m, 2H, H-1 and H-
6), 8.53e8.51 (m, 1H, H-40), 8.26e8.11 (m, 5H, H-8, H-9, H-20, H-60
and H-200), 7.95e7.88 (m, 2H, H-3 and H-600), 7.54e7.50 (m, 1H, H-
50), 7.46e7.41 (m, 1H, H-500), 7.20e7.17 (m, 1H, H-400), 4.38 (q, 2H,
J ¼ 6.90 Hz, OCH2), 4.23 (s, 1H, C^CH), 1.37 (t, 3H, J ¼ 6.90 Hz, CH3).
Anal. Calcd. for C27H20N4O2: C, 74.99; H, 4.66; N, 12.95. Found: C,
75.13; H, 4.78; N, 12.81.
6.1.11. General procedure for 4-[(3-substituted-phenyl)amino]
pyrrolo[1,2-a]quinoxaline-carboxylic acids (1aej) and ethyl 7-[(3-
substituted-phenyl)amino]pyrrolo[1,2-a]quinoxaline-4-carboxylic
acids 1k,l and ethyl 4-[(3-substituted-phenyl)amino]-2-(3-pyridyl)
pyrrolo[1,2-a]quinoxaline-7-carboxylic acids 1m,n
Amixture of ethyl 4-[(3-substituted-phenyl)amino]pyrrolo[1,2-a]
quinoxaline-carboxylates 12aej or ethyl 7-[(3-substituted-phenyl)
amino]pyrrolo[1,2-a]quinoxaline-4-carboxylates12k,lorethyl 4-[(3-
substituted-phenyl)amino]-2-(3-pyridyl)pyrrolo[1,2-a]quinoxaline-
7-carboxylates 12m,n (0.6 mmol) in methanol (15 mL) and a NaOH
aqueous solution (4.8mmol in 8mL)was reﬂuxed for 4 h. On cooling,
after removal of the solvent under reduced pressure, the residuewas
diluted with water and adjusted to pH ¼ 6 with 1 M HCl aqueous
solution. The solid precipitatewasﬁltered off andwashedwithwater
then with diethyl ether, and puriﬁed by column chromatography
using CH2Cl2/methanol (9/1, v/v) as eluent to give 1aen.
6.1.11.1. 4-[(3-Chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-2-
carboxylic acid (1a). Pale-yellow crystals (91%); mp >300 C. IR
(KBr) 3290 (NH), 3100e2650 (COOH), 1685 (COO). 1H NMR (DMSO-
d6) d: 12.10 (bs, 1H, COOH), 9.43 (s, 1H, NH), 8.44e8.43 (m, 2H, H-1
and H-20), 8.16e8.10 (m, 2H, H-9 and H-60), 7.73 (d, 1H, J ¼ 1.50 Hz,
H-3), 7.59 (dd, 1H, J¼ 7.90 and 1.35 Hz, H-6), 7.39e7.30 (m, 3H, H-7,
H-8 and H-50), 7.03 (dd, 1H, J ¼ 8.10 and 1.50 Hz, H-40). 13C NMR
(DMSO-d6) d: 168.1, 146.6, 142.0, 135.0, 132.2, 129.7, 129.5, 126.2,
125.0, 124.7, 123.6, 120.6, 118.6, 117.7, 117.5, 117.0, 113.8, 106.6. Anal.
Calcd. for C18H12ClN3O2: C, 64.01; H, 3.58; N, 12.44. Found: C, 63.85;
H, 3.43; N, 12.77.
6.1.11.2. 4-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-2-
carboxylic acid (1b). Beige crystals (90%); mp >300 C. IR (KBr)
3285 (NH), 3150e2600 (COOH), 2105 (C^C), 1685 (COO). 1H NMR
(DMSO-d6) d: 9.43 (s, 1H, NH), 8.58 (d, 1H, J ¼ 1.35 Hz, H-1), 8.35 (d,
1H, J ¼ 1.70 Hz, H-20), 8.23 (d, 1H, J ¼ 7.80 Hz, H-9), 8.16 (d, 1H,
J ¼ 7.80 Hz, H-60), 7.84 (d, 1H, J ¼ 1.35 Hz, H-3), 7.58 (d, 1H,
J ¼ 7.80 Hz, H-6), 7.40e7.28 (m, 3H, H-7, H-8 and H-50), 7.12 (d, 1H,
J ¼ 7.80 Hz, H-40), 5.80 (bs, 1H, COOH), 4.19 (s, 1H, C^CH). 13C NMR
(DMSO-d6) d: 172.9, 167.4, 146.5, 140.5, 135.3, 128.3, 126.3, 125.6,
125.1, 124.7, 123.5, 122.4, 121.2, 120.2, 118.1, 117.9, 113.9, 106.5, 83.4,
79.6. Anal. Calcd. for C20H13N3O2: C, 73.38; H, 4.00; N, 12.84. Found:
C, 73.18; H, 3.86; N, 12.70.
6.1.11.3. 4-[(3-Chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-3-
carboxylic acid (1c). Pale-yellow crystals (84%); mp 229 C. IR (KBr)
3300 (NH), 3100e2600 (COOH), 1685 (COO). 1H NMR (DMSO-d6) d:
13.60 (s, 1H, NH), 8.40 (d, 1H, J ¼ 3.00 Hz, H-1), 8.39 (t, 1H,
J ¼ 2.10 Hz, H-20), 8.24 (dd, 1H, J ¼ 7.90 and 1.50 Hz, H-9), 7.78 (dd,
1H, J ¼ 8.10 and 1.10 Hz, H-60), 7.66 (1H, J ¼ 7.90 and 1.50 Hz, H-6),
7.47e7.37 (m, 2H, H-7 and H-8), 7.39 (t, 1H, J ¼ 8.10 Hz, H-50),
7.27 (d, 1H, J ¼ 3.00 Hz, H-2), 7.09e7.06 (m, 1H, H-40). 13C NMR
(DMSO-d6) d: 167.9, 145.6, 141.6, 135.2, 132.7, 129.9, 129.8, 126.0,
125.9, 123.9, 123.7, 120.9, 119.3, 118.0, 117.0, 116.4, 115.3, 114.4. Anal.
Calcd. for C18H12ClN3O2: C, 64.01; H, 3.58; N, 12.44. Found: C, 63.94;
H, 3.63; N, 12.67.
6.1.11.4. 4-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-3-
carboxylic acid (1d). Yellow crystals (81%); mp 210 C. IR (KBr) 3280(NH), 3100e2650 (COOH), 2100 (C^C), 1685 (COO). 1H NMR
(DMSO-d6) d: 13.73 (s, 1H, NH), 8.34 (d,1H, J¼ 3.00 Hz, H-1), 8.23 (t,
1H, J ¼ 1.90 Hz, H-20), 8.18 (dd, 1H, J ¼ 7.80 and 1.50 Hz, H-9), 8.03
(dd,1H, J¼ 8.10 and 1.10 Hz, H-60), 7.64 (dd,1H, J¼ 7.80 and 1.50 Hz,
H-6), 7.43e7.35 (m, 3H, H-7, H-8 and H-50), 7.26 (d, 1H, J ¼ 3.00 Hz,
H-2), 7.14e7.11 (m, 1H, H-40), 4.14 (s, 1H, C^CH). 13C NMR (DMSO-
d6) d: 167.9, 145.8, 140.5, 135.4, 128.8, 128.7, 125.9, 125.8, 124.5,
123.8, 123.5, 121.6, 121.4, 119.2, 119.1, 116.4, 115.0, 114.3, 83.3, 79.8.
Anal. Calcd. for C20H13N3O2: C, 73.38; H, 4.00; N, 12.84. Found: C,
73.54; H, 3.85; N, 12.98.
6.1.11.5. 4-[(3-Chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-7-
carboxylic acid (1e). Beige crystals (96%); mp >300 C. IR (KBr)
3425 (NH), 3150e2600 (COOH), 1700 (COO). 1H NMR (DMSO-d6) d:
12.85 (bs, 1H, COOH), 9.47 (s, 1H, NH), 8.41e8.38 (m, 2H, H-1 and H-
6), 8.19 (d, 1H, J ¼ 8.70 Hz, H-9), 8.16 (d, 1H, J ¼ 1.50 Hz, H-20), 8.06
(dd,1H, J¼ 8.70 and 1.60 Hz, H-8), 7.88 (dd,1H, J¼ 8.70 and 1.50 Hz,
H-60), 7.50 (dd,1H, J¼ 3.65 and 1.20 Hz, H-3), 7.40 (t,1H, J¼ 8.70 Hz,
H-50), 7.08 (dd, 1H, J ¼ 8.70 and 1.50 Hz, H-40), 6.90 (dd, 1H, J ¼ 3.65
and 3.00 Hz, H-2). 13C NMR (DMSO-d6) d: 167.2, 146.3, 141.5, 134.4,
132.3, 129.6, 129.1, 127.4, 127.3, 124.3, 121.1, 118.9, 118.4, 117.9, 116.5,
113.7, 112.9, 105.4. Anal. Calcd. for C18H12ClN3O2: C, 64.01; H, 3.58;
N, 12.44. Found: C, 64.28; H, 3.70; N, 12.63.
6.1.11.6. 4-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-7-
carboxylic acid (1f). Beige crystals (65%); mp 280 C. IR (KBr) 3400
(NH), 3250e2500 (COOH), 2100 (C^C), 1685 (COO). 1H NMR
(DMSO-d6) d: 13.07 (s, 1H, COOH), 9.36 (s, 1H, NH), 8.43e8.41 (m,
1H, H-1), 8.28e8.15 (m, 3H, H-9, H-6 and H-8), 8.13 (d, 1H,
J ¼ 1.70 Hz, H-20), 7.86 (dd, 1H, J ¼ 8.30 and 1.70 Hz, H-60), 7.46 (dd,
1H, J ¼ 3.80 and 1.20 Hz, H-3), 7.41 (t, 1H, J ¼ 8.30 Hz, H-50), 7.16
(dd, 1H, J ¼ 8.30 and 1.70 Hz, H-40), 6.91 (dd, 1H, J ¼ 3.80 and
2.90 Hz, H-2), 4.22 (s, 1H, C^CH). 13C NMR (DMSO-d6) d: 166.6,
146.5, 140.1, 134.7, 128.4, 127.8, 127.4, 127.3, 124.8, 124.1, 122.6,
121.2, 120.4, 118.4, 116.5, 113.9, 113.0, 105.4, 83.2, 79.7. Anal. Calcd.
for C20H13N3O2: C, 73.38; H, 4.00; N, 12.84. Found: C, 73.51; H,
3.93; N, 12.99.
6.1.11.7. 4-[(3-Chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-8-
carboxylic acid (1g). Beige crystals (81%); mp >300 C. IR (KBr)
3420 (NH), 3100e2600 (COOH), 1690 (COO). 1H NMR (DMSO-d6) d:
9.50 (s, 1H, NH), 8.61 (d, 1H, J ¼ 1.70 Hz, H-9), 8.49e8.47 (m, 1H, H-
1), 8.34 (t, 1H, J ¼ 1.80 Hz, H-20), 8.03 (d, 1H, J ¼ 8.40 Hz, H-7), 8.03
(d,1H, J¼ 8.40 Hz, H-7), 7.91 (dd,1H, J¼ 8.10 and 1.80 Hz, H-60), 7.62
(d,1H, J¼ 8.40 Hz, H-6), 7.46 (dd,1H, J¼ 3.90 and 1.10 Hz, H-3), 7.40
(t, 1H, J¼ 8.10 Hz, H-50), 7.10 (dd,1H, J¼ 8.10 and 1.80 Hz, H-40), 6.87
(dd, 1H, J ¼ 3.90 and 3.00 Hz, H-2), 3.39 (bs, 1H, COOH). 13C NMR
(DMSO-d6) d: 166.7, 147.1, 141.3, 138.1, 132.3, 129.6, 129.5, 125.9,
125.7, 124.4, 121.4, 119.3, 118.3, 118.1, 116.6, 114.8, 112.6, 105.4. Anal.
Calcd. for C18H12ClN3O2: C, 64.01; H, 3.58; N, 12.44. Found: C, 63.86;
H, 3.67; N, 12.28.
6.1.11.8. 4-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-8-
carboxylic acid (1h). White crystals (76%); mp >300 C. IR (KBr)
3390 (NH), 3150e2600 (COOH), 2100 (C^C), 1690 (COO). 1H NMR
(DMSO-d6) d: 9.43 (s, 1H, NH), 8.62 (d, 1H, J ¼ 1.80 Hz, H-9), 8.42e
8.41 (m, 1H, H-1), 8.29 (t, 1H, J ¼ 1.75 Hz, H-20), 8.19 (d, 1H,
J ¼ 8.20 Hz, H-7), 7.93 (d, 1H, J ¼ 8.40 Hz, H-60), 7.58 (d, 1H,
J¼ 8.20 Hz, H-6), 7.54 (dd, 1H, J¼ 3.80 and 1.20 Hz, H-3), 7.38 (t, 1H,
J¼ 8.40 Hz, H-50), 7.15 (d,1H, J¼ 8.40 Hz, H-40), 6.84 (dd,1H, J¼ 3.80
and 3.00 Hz, H-2), 4.21 (s, 1H, C^CH), 3.61 (bs, 1H, COOH). 13C NMR
(DMSO-d6) d: 168.0, 147.0, 140.1, 137.8, 128.5, 128.3, 125.7, 125.6,
124.9, 124.2, 122.8, 121.2, 120.6, 118.2, 116.2, 114.7, 112.5, 105.4, 83.2,
79.7. Anal. Calcd. for C20H13N3O2: C, 73.38; H, 4.00; N, 12.84. Found:
C, 73.44; H, 3.95; N, 12.80.
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carboxylic acid (1i). Beige crystals (52%); mp>300 C. IR (KBr) 3410
(NH), 3100e2600 (COOH), 1690 (COO). 1H NMR (DMSO-d6) d: 9.38
(s, 1H, NH), 8.31 (t, 1H, J ¼ 1.80 Hz, H-20), 8.05e8.00 (m, 1H, H-60),
7.92 (dd, 1H, J ¼ 2.90 and 1.20 Hz, H-1), 7.66 (dd, 1H, J ¼ 7.50 and
1.65 Hz, H-6), 7.47 (dd, 1H, J ¼ 4.05 and 1.20 Hz, H-3), 7.40e7.32 (m,
3H, H-7, H-8 and H-50), 7.08 (dd, 1H, J¼ 7.50 and 1.65 Hz, H-40), 6.86
(dd, 1H, J ¼ 4.05 and 2.90 Hz, H-2), 3.43 (bs, 1H, COOH). 13C NMR
(DMSO-d6) d: 171.1, 147.2, 142.5, 137.0, 133.3, 130.6, 129.1, 125.3,
124.5, 124.3, 122.2, 121.9, 120.1, 120.0, 119.7, 119.0, 133.3, 105.8. Anal.
Calcd. for C18H12ClN3O2: C, 64.01; H, 3.58; N, 12.44. Found: C, 63.98;
H, 3.62; N, 12.37.
6.1.11.10. 4-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-9-
carboxylic acid (1j). Beige crystals (75%); mp 214 C. IR (KBr) 3385
(NH), 3150e2650 (COOH), 2100 (C^C),1690 (COO). 1H NMR (DMSO-
d6) d: 9.20 (s, 1H, NH), 8.38 (dd,1H, J¼ 2.95 and 1.20 Hz, H-1), 8.27 (t,
1H, J ¼ 1.70 Hz, H-20), 8.18 (dd, 1H, J ¼ 7.40 and 1.50 Hz, H-60), 7.46e
7.40 (m, 2H, H-3 and H-6), 7.36 (t, 1H, J ¼ 7.95 Hz, H-7), 7.23 (t, 1H,
J ¼ 7.65 Hz, H-50), 7.12e7.10 (m, 1H, H-8), 7.07 (dd, 1H, J ¼ 7.40 and
1.50 Hz, H-40), 6.69 (dd, 1H, J ¼ 3.90 and 2.95 Hz, H-2), 4.19 (s, 1H,
C^CH), 3.50 (bs,1H, COOH).13CNMR (DMSO-d6) d: 173.0,146.8,141.6,
136.6, 133.0,129.3, 125.4, 125.3, 124.9,123.3, 122.8, 122.2, 121.1, 120.8,
120.6, 119.6, 111.9, 105.0, 84.4, 80.6. Anal. Calcd. for C20H13N3O2: C,
73.38; H, 4.00; N, 12.84. Found: C, 73.25; H, 3.85; N, 12.93.
6.1.11.11. 7-[(3-Chlorophenyl)amino]pyrrolo[1,2-a]quinoxaline-4-
carboxylic acid (1k). Red crystals (56%); mp 195 C. IR (KBr) 3405
(NH), 3300e2700 (COOH), 1675 (COO). 1H NMR (DMSO-d6) d: 8.75
(s, 1H, NH), 8.48e8.47 (m, 1H, H-1), 8.27 (d, 1H, J ¼ 6.70 Hz, H-9),
7.66 (d,1H, J¼ 1.80 Hz, H-6), 7.43 (dd,1H, J¼ 6.70 and 1.20 Hz, H-8),
7.38e7.36 (m, 1H, H-3), 7.29 (t, 1H, J ¼ 6.10 Hz, H-50), 7.13e7.09 (m,
2H, H-40 and H-20), 6.98e6.96 (m, 1H, H-2), 6.89 (d, 1H, J ¼ 6.10 Hz,
H-60), 3.43 (bs, 1H, COOH). 13C NMR (DMSO-d6) d: 165.9, 149.7,
145.0, 139.2, 135.1, 133.1, 130.3, 123.7, 121.6, 119.9, 118.4, 116.2, 115.0,
114.8, 114.6, 113.7, 113.3, 109.2. Anal. Calcd. for C18H12ClN3O2: C,
64.01; H, 3.58; N, 12.44. Found: C, 63.82; H, 3.62; N, 12.40.
6.1.11.12. 7-[(3-Ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-4-
carboxylic acid (1l). Orange crystals (73%); mp >300 C. IR (KBr)
3355 (NH), 3400e2850 (COOH), 2100 (C^C), 1630 (COO). 1H NMR
(DMSO-d6) d: 8.49 (s, 1H, NH), 8.26e8.25 (m, 1H, H-1), 8.12 (d, 1H,
J ¼ 8.70 Hz, H-9), 7.73 (d, 1H, J¼ 2.00 Hz, H-6), 7.29e7.14 (m, 5H, H-
3, H-20, H-40, H-50 and H-8), 6.91 (d, 1H, J ¼ 7.10 Hz, H-60), 6.81 (dd,
1H, J ¼ 3.85 and 2.70 Hz, H-2), 4.10 (s, 1H, C^CH), 3.41 (bs, 1H,
COOH). 13C NMR (DMSO-d6) d: 167.5, 154.4, 144.7, 140.1, 136.7, 130.1,
125.1, 123.1, 123.0, 122.4, 119.9, 119.0, 117.4, 116.8, 115.7, 115.0, 113.7,
110.1, 84.3, 80.6. Anal. Calcd. for C20H13N3O2: C, 73.38; H, 4.00; N,
12.84. Found: C, 73.56; H, 3.89; N, 12.93.
6.1.11.13. 4-[(3-Chlorophenyl)amino]-2-(3-pyridyl)pyrrolo[1,2-a]qui-
noxaline-7-carboxylic acid (1m). Beige crystals (92%); mp >300 C.
IR (KBr) 3385 (NH), 3600e3000 (COOH), 1690 (COO). 1H NMR
(DMSO-d6) d: 9.59 (s, 1H, NH), 9.07e9.06 (m, 1H, H-1), 8.99e8.98
(m, 1H, H-6), 8.49e8.48 (m, 2H, H-40 and H-9), 8.17e8.16 (m, 2H, H-
60 and H-20), 8.12e8.10 (m, 2H, H-200 and H-8), 7.94e7.92 (m, 2H, H-
3 and H-600), 7.51e7.48 (m, 1H, H-50), 7.42e7.40 (m, 1H, H-500), 7.09e
7.07 (m, 1H, H-400), 3.42 (bs, 1H, COOH). 13C NMR (DMSO-d6) d:
169.3, 148.4, 147.3, 146.8, 143.0, 139.2, 135.2, 133.5, 133.1, 130.7,
130.6,128.5, 126.2, 126.1, 125.0, 124.7, 121.9, 120.6, 119.8,118.7, 114.4,
113.8, 103.0. Anal. Calcd. for C23H15ClN4O2: C, 66.59; H, 3.64; N,
13.51. Found: C, 66.72; H, 3.62; N, 13.43.
6.1.11.14. 4-[(3-Ehtynylphenyl)amino]-2-(3-pyridyl)pyrrolo[1,2-a]
quinoxaline-7-carboxylic acid (1n). Beige crystals (83%); mp>300 C. IR (KBr) 3355 (NH), 3650e2900 (COOH), 2105 (C^C),1695
(COO). 1H NMR (DMSO-d6) d: 13.04 (s, 1H, COOH), 9.54 (s, 1H, NH),
9.07 (s, 1H, H-1), 9.06 (s, 1H, H-6), 8.54e8.53 (m, 1H, H-40), 8.32 (s,
1H, H-20), 8.27e8.22 (m, 2H, H-60 and H-9), 8.19e8.17 (m, 1H, H-8),
8.14 (s, 1H, H-200), 8.01 (s, 1H, H-3), 7.92e7.90 (m, 1H, H-600), 7.56e
7.53 (m, 1H, H-50), 7.44e7.41 (m, 1H, H-500), 7.19e7.17 (m, 1H, H-400),
4.20 (s, 1H, C^CH). 13C NMR (DMSO-d6) d: 167.5, 148.2, 147.4, 146.9,
141.2, 135.9, 133.4, 130.4, 129.6, 128.7, 128.6, 128.4, 126.1, 125.5,
125.4, 124.8, 123.6, 122.4, 121.4, 120.7, 115.2, 115.1, 104.0, 84.4, 80.9.
Anal. Calcd. for C25H16N4O2: C, 74.25; H, 3.99; N, 13.85. Found: C,
74.09; H, 3.82; N, 13.75.
6.1.12. 1-(4-Bromo-2-nitrophenyl)pyrrole (13)
A mixture of 4-bromo-2-nitroaniline (23 mmol) and 2,5-
dimethoxytetrahydrofuran (25 mmol) in acetic acid (65 mL) was
reﬂuxed for 1 h with vigourous stirring. After cooling, the reaction
mixture was poured into water. The mixture was then extracted
twice with diethyl ether. The organic layer was dried over sodium
sulfate and evaporated to dryness under reduced pressure to give
13. Orange oil (86%). 1H NMR (CDCl3) d: 8.00 (d, 1H, J ¼ 2.20 Hz,
H-3), 7.78 (dd,1H, J¼ 8.55 and 2.20 Hz, H-5), 7.36 (d,1H, J¼ 8.55 Hz,
H-6), 6.78 (dd, 2H, J ¼ 1.85 and 1.85 Hz, 2H-a), 6.39 (dd, 2H, J ¼ 1.85
and 1.85 Hz, 2H-b). Anal. Calcd. for C10H7BrN2O2: C, 44.97; H, 2.64;
N, 10.49. Found: C, 45.12; H, 2.85; N, 10.38.
6.1.13. 1-(2-Amino-4-bromophenyl)pyrrole (14)
To a solution of 1-(4-bromo-2-nitrophenyl)pyrrole (13)
(19 mmol) in ethanol (95 mL) was added 15 mL of a 2 M aqueous
solution of CuSO4. Sodium borohydride (94 mmol) was added
portion-wise at 0 C to the reaction mixture which was then stirred
at room temperature for 1 h. The reaction mixture was then diluted
with ethyl acetate and ﬁltered. The organic layer was separated,
dried over Na2SO4 and evaporated to dryness under reduced
pressure to give 14. Orange crystals (90%); mp 67 C. IR (KBr) 3380
and 3300 (NH2). 1H NMR (CDCl3) d: 7.01 (d, 1H, J ¼ 8.10 Hz, H-6),
6.97 (d,1H, J¼ 1.80 Hz, H-3), 6.92 (dd,1H, J¼ 8.10 and 1.80 Hz, H-5),
6.81 (dd, 2H, J ¼ 1.80 and 1.80 Hz, 2H-a), 6.36 (dd, 2H, J ¼ 1.80 and
1.80 Hz, 2H-b), 3.81 (bs, 2H, NH2). Anal. Calcd. for C10H9BrN2: C,
50.66; H, 3.83; N, 11.82. Found: C, 50.85; H, 4.02; N, 11.97.
6.1.14. Ethyl 2-[(5-bromo-2-pyrrolo-1-ylphenyl)amino]-2-oxo-
acetate (15)
To a solution containing 1-(2-amino-4-bromophenyl)pyrrole
(14) (17 mmol) in 140 mL of THF at 0 C was added Et3N (17 mmol)
followed by ethyl oxalylchloride (17 mmol) dropwise over 15 min.
The reaction mixturewas warmed to room temperature and stirred
for 14 h. The reaction mixture was ﬁltered and the ﬁlter cake was
washed with THF then with ethyl acetate. The organic phase was
washed twice with 25 mL of a 1 M HCl aqueous solution, dried over
sodium sulfate, ﬁltered, and concentrated. The crude residue was
cooled, triturated with diethyl ether and ﬁltered to give 15. Beige
crystals (43%); mp 70 C. IR (KBr) 3280 (NH),1690 and 1680 (CO). 1H
NMR (CDCl3) d: 8.90 (s, 1H, NH), 8.75 (d, 1H, J ¼ 1.80 Hz, H-6), 7.40
(dd,1H, J¼ 8.40 and 1.80 Hz, H-5), 7.23 (d,1H, J¼ 8.40 Hz, H-3), 6.80
(dd, 2H, J ¼ 1.80 and 1.80 Hz, 2H-a), 6.48 (dd, 2H, J ¼ 1.80 and
1.80 Hz, 2H-b), 4.36 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.39 (t, 3H,
J¼ 7.20 Hz, CH3). Anal. Calcd. for C14H13BrN2O3: C, 49.87; H, 3.89; N,
8.31. Found: C, 50.04; H, 3.73; N, 8.35.
6.1.15. Ethyl 4-bromopyrrolo[1,2-a]quinoxaline-4-carboxylate (16)
A solution of ethyl 2-[(5-bromo-2-pyrrolo-1-ylphenyl)amino]-
2-oxo-acetate (15) (7 mmol) in POCl3 (10 mL) was reﬂuxed for
20 min. After removing excess of reactive under vacuum, the res-
idue was carefully dissolved in water at 0 C and the resulting so-
lution was made basic with ammonium hydroxide. The precipitate
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crystals (70%); mp 159 C. IR (KBr) 1735 (COO). 1H NMR (CDCl3) d:
8.33 (d,1H, J¼ 2.10 Hz, H-6), 8.03 (dd,1H, J¼ 2.80 and 1.20 Hz, H-1),
7.79 (d,1H, J¼ 8.90 Hz, H-9), 7.72 (dd,1H, J¼ 8.90 and 2.10 Hz, H-8),
7.57 (dd, 1H, J ¼ 3.90 and 1.20 Hz, H-3), 7.03 (dd, 1H, J ¼ 3.90 and
2.80 Hz, H-2), 4.60 (q, 2H, J¼ 7.20 Hz, OCH2), 1.54 (t, 3H, J¼ 7.20 Hz,
CH3). Anal. Calcd. for C14H11BrN2O2: C, 52.69; H, 3.47; N, 8.78.
Found: C, 52.78; H, 3.33; N, 8.89.
6.1.16. Ethyl 7-[(3-ethynylphenyl)amino]pyrrolo[1,2-a]quinoxaline-
4-carboxylate (17)
To a solution of ethyl 7-{[3-(2-trimethylsilylethynyl)phenyl]
amino}pyrrolo[1,2-a]quinoxaline-4-carboxylate (12l) (0.5 mmol) in
THF (5 mL), cooled to20 C, 0.6 mL of a 1 M tetrabutylammonium
ﬂuoride solution in THF was added and the mixture was stirred for
1 h. The mixture was diluted with water and extracted twice with
ethyl acetate. The extract was washed with water, brine, dried with
sodium sulfate and evaporated to leave an orange solid which was
puriﬁed by column chromatography (silica gel, cyclohexane/ethyl
acetate, 7/3, v/v). Orange crystals (69%); mp 68 C. IR (KBr) 3420
(NH), 2105 (C^C), 1720 (COO). 1H NMR (CDCl3) d: 7.95 (dd, 1H,
J ¼ 2.55 and 1.20 Hz, H-1), 7.80 (d, 1H, J ¼ 2.10 Hz, H-6), 7.78 (d, 1H,
J ¼ 8.40 Hz, H-9), 7.51 (dd, 1H, J ¼ 4.05 and 1.20 Hz, H-3), 7.33 (dd,
1H, J ¼ 8.40 and 2.10 Hz, H-8), 7.25 (t, 1H, J ¼ 1.70 Hz, H-20), 7.24 (t,
1H, J¼ 8.10 Hz, H-50), 7.15e7.09 (m, 2H, H-40 and H-60), 6.96 (dd,1H,
J ¼ 4.05 and 2.55 Hz, H-2), 6.28 (s, 1H, NH), 4.54 (q, 2H, J ¼ 6.90 Hz,
OCH2), 1.46 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd. for C22H17N3O2: C,
74.35; H, 4.82; N, 11.82. Found: C, 74.52; H, 5.06; N, 11.94.
6.1.17. Ethyl 7-[2-(3-aminophenyl)ethynyl]pyrrolo[1,2-a]
quinoxaline-4-carboxylate (18)
A mixture of 7-bromopyrrolo[1,2-a]quinoxaline (16) (3 mmol),
3-ethynylaniline (3.6 mmol), Cs2CO3 (4.2 mmol), Pd(OAc)2
(0.15 mmol) and BINAP (0.225 mmol) in 15 mL of toluene was
heated at 100 C for 20 h. The reaction mixture was allowed to cool
to room temperature, diluted with dichloromethane and ﬁltered
through a pad of Celite and the ﬁlter cake was washed with
dichloromethane (3). Concentration and ﬂash chromatography on
silica gel using AcOEt/cyclohexane (3/7, v/v) as eluent afforded 18.
Orange crystals (22%); mp 145 C. IR (KBr) 3410 and 3330 (NH2),
2210 (C^C), 1725 (COO). 1H NMR (CDCl3) d: 8.32 (d, 1H, J ¼ 1.80 Hz,
H-6), 8.03 (dd,1H, J¼ 2.70 and 1.20 Hz, H-1), 7.88 (d,1H, J¼ 8.40 Hz,
H-9), 7.76 (dd, 1H, J ¼ 8.10 and 1.80 Hz, H-8), 7.57 (dd, 1H, J ¼ 4.05
and 1.20 Hz, H-3), 7.18 (t, 1H, J¼ 8.10 Hz, H-50), 7.03 (dd, 1H, J¼ 4.05
and 2.70 Hz, H-2), 7.01e6.98 (m,1H, H-60), 6.91 (t,1H, J¼ 1.80 Hz, H-
20), 6.73e6.69 (m, 1H, H-40), 4.62 (q, 2H, J ¼ 7.20 Hz, OCH2), 3.75 (s,
2H, NH2), 1.55 (t, 3H, J ¼ 7.20 Hz, CH3). Anal. Calcd. for C22H17N3O2:
C, 74.35; H, 4.82; N, 11.82. Found: C, 74.28; H, 5.01; N, 11.89.
6.1.18. 7-[2-(3-Aminophenyl)ethynyl]pyrrolo[1,2-a]quinoxaline-4-
carboxylic acid (19)
A mixture of ethyl 7-[2-(3-aminophenyl)ethynyl]pyrrolo[1,2-a]
quinoxaline-4-carboxylate (18) (0.6mmol) inmethanol (12mL) and
aNaOHaqueous solution (4.8mmol in 8mL)was reﬂuxed for 4 h. On
cooling, after removal of the solvent under reduced pressure, the
residuewas dilutedwithwater and adjusted to pH¼ 6with 1MHCl
aqueous solution. The solid precipitate was ﬁltered off and washed
with water then with diethyl ether, and puriﬁed by column chro-
matography using CH2Cl2/methanol (9/1, v/v) as eluent to give 19.
Beige crystals (45%);mp>300 C. IR (KBr) 3500e2900 (COOH), 3400
and 3340 (NH2), 2205 (C^C), 1695 (COO). 1H NMR (DMSO-d6) d:
10.21 (s, 1H, COOH), 8.42e8.40 (m,1H, H-1), 8.26 (d, 1H, J¼ 7.80 Hz,
H-9), 8.10 (s,1H, H-6), 7.67 (d,1H, J¼ 7.80Hz, H-8), 7.30e7.29 (m,1H,
H-3), 7.07 (t,1H, J¼7.60Hz,H-50), 6.91e6.90 (m,1H,H-2), 6.77 (s,1H,
H-20), 6.72 (d,1H, J¼7.60Hz,H-60), 6.61 (d,1H, J¼7.60Hz,H-40), 5.28(s, 2H, NH2). 13C NMR (DMSO-d6) d: 165.8, 148.4, 134.7, 131.8, 129.8,
128.8, 126.9, 124.2, 121.9, 118.5, 118.3, 115.7, 115.3, 114.6, 114.2, 113.8,
109.8,104.1, 89.9, 87.0. Anal. Calcd. for C20H13N3O2: C, 73.38; H, 4.00;
N, 12.84. Found: C, 73.21; H, 4.18; N, 12.94.
6.1.19. Methyl 4-(3-pyridyl)-1H-pyrrole-2-carboxylate (22)
To suspension of 4-bromopyrrole-1,2-dicarboxylic acid 1-tert-
butyl ester 2-methyl ester (21) (10 mmol), and Pd(PPh3)4
(0.5mmol) in a mixture of toluene/EtOH (120/6mL) under nitrogen
were added K2CO3 (11 mmol) and 3-pyridylboronic acid (11 mmol).
The reaction mixture was reﬂuxed for 24 h, and the cooled sus-
pension was extracted with CH2Cl2 (3  100 mL). The organic layer
was washed with a saturated solution of NaCl (150 mL), and the
combined organic extracts were dried over sodium sulfate, ﬁltered,
and evaporated under reduced pressure. The crude residue was
solubilized in 40 mL of dichloromethane. To this reaction mixture
was added 100 mL of a 10% triﬂuoroacetic acid solution in
dichloromethane. The mixture was stirred at room temperature for
4 h, then neutralized with 300 mL of a saturated aqueous solution
of potassium carbonate and extracted with 120 mL of dichloro-
methane. The organic layer was washed with water, then brine and
dried with anhydrous sodium sulfate. The solvent was removed
under reduced pressure. The residue was triturated in methanol,
then the resulting precipitate was ﬁltered, washed with MeOH and
dried to give 22. White crystals (34%); mp 177 C. IR (KBr) 3390
(NH), 1700 (COO). 1H NMR (CDCl3) d: 10.30 (s, 1H, NH), 8.83 (s, 1H,
H-3), 8.48 (d, 1H, J ¼ 4.50 Hz, H-40), 7.80 (d, 1H, J ¼ 7.80 Hz, H-60),
7.33e7.28 (m, 2H, H-20 and H-60), 7.23 (s, 1H, H-5), 3.90 (s, 3H,
OCH3). Anal. Calcd. for C11H10N2O2: C, 65.34; H, 4.98; N, 13.85.
Found: C, 65.52; H, 5.06; N, 13.98.
6.1.20. Methyl 1-(4-ethoxycarbonyl-2-nitrophenyl)-4-(3-pyridyl)-
1H-pyrrole-2-carboxylate (23)
To the solution of methyl 4-(3-pyridyl)-1H-pyrrole-2-
carboxylate (22) (3.3 mmol) in 12 mL of DMF was added cesium
carbonate (4 mmol). The mixture was stirred at room temperature
for 10 min, then ethyl 4-ﬂuoro-3-nitrobenzoate (4 mmol) was
added. The reaction mixture was reﬂuxed for 1 h 30 min was then
diluted in AcOEt (50 mL), was washed with water (2  50 mL), then
brine (50 mL) and dried over sodium sulfate. The organic layer was
concentrated under vacuo to give a brown oil. After triturating in
Et2O a solid was obtained and ﬁltered off, washed with Et2O and
dried to give the desired product 23. Orange crystals (69%); mp
163 C. IR (KBr) 1710 (COO). 1H NMR (CDCl3) d: 8.85 (s,1H, H-3), 8.80
(d, 1H, J ¼ 1.80 Hz, H-30), 8.54e8.52 (m, 1H, H-400), 8.41 (dd, 1H,
J¼ 8.20 and 1.80 Hz, H-50), 7.84 (d,1H, J¼ 7.80 Hz, H-600), 7.59 (d,1H,
J ¼ 8.20 Hz, H-60), 7.45 (d, 1H, J ¼ 1.80 Hz, H-200), 7.35 (dd, 1H,
J¼ 7.80 and 4.90 Hz, H-500), 7.29 (s, 1H, H-5), 4.49 (q, 2H, J¼ 6.90 Hz,
OCH2), 3.75 (s, 3H, OCH3), 1.47 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd.
for C20H17N3O6: C, 60.76; H, 4.33; N, 10.63. Found: C, 60.83; H, 4.38;
N, 10.52.
6.2. X-ray data
The structure of compounds 1f, 16 and 22 has been established
by X-ray crystallography (Figs. 3e5). Colorless single crystal
(0.10  0.06  0.05 mm3) of 1f was obtained by slow evaporation
from methanol/chloroform (30/70) solution: monoclinic, space
group P21/n, a ¼ 4.8092(4) A, b ¼ 33.851(3) A, c ¼ 9.6672(8) A,
a ¼ 90, b ¼ 101.440(6), g ¼ 90, V ¼ 1542.5(2) A3, Z ¼ 4,
d(calcd) ¼ 1.410 Mg m3, FW ¼ 327.33 for C20H13N3O2,
F(000) ¼ 680. Yellow single crystal (0.12  0.07  0.07 mm3) of 16
was obtained by slow evaporation from methanol/dichloro-
methane (30/70) solution: monoclinic, space group P21/c,
a ¼ 4.047(3) A, b ¼ 21.371(3) A, c ¼ 14.738(4) A, a ¼ 90,
J. Guillon et al. / European Journal of Medicinal Chemistry 65 (2013) 205e222 221b ¼ 96.03(3), g ¼ 90, V ¼ 1267.6(10) A3, Z ¼ 4,
d(calcd) ¼ 1.672 Mg m3, FW ¼ 319.16 for C14H11BrN2O2,
F(000) ¼ 640. Yellow single crystal (0.15  0.10  0.10 mm3) of 22
was obtained by slow evaporation from methanol/chloroform (30/
70) solution: monoclinic, space group P21/n, a ¼ 5.4906(5) A,
b ¼ 14.0619(7)A, c¼ 12.9743(7)A, a¼ 90, b¼ 94.431(3), g ¼ 90,
V ¼ 998.73(12)A3, Z ¼ 4, d(calcd) ¼ 1.345 Mg m3, FW ¼ 202.21 for
C11H10N2O2, F(000) ¼ 424. Full crystallographic results have been
deposited at the Cambridge Crystallographic Data Centre (CCDC-
888291, CCDC-912632 and CCDC-884533), UK, as Supplementary
material [33]. The data were corrected for Lorentz and polariza-
tion effects and for empirical absorption correction [50]. The
structure was solved by direct methods Shelx 86 [51] and reﬁned
using Shelx 93 [52] suite of programs.
6.3. Biological assays
6.3.1. Preparation of recombinant human CK2 holoenzyme
The preparation of the human recombinant CK2 holoenzyme
was performed according to a protocol described previously [42].
For the expression of the a-subunit (CSNK2A1) and b-subunit
(CSNK2B) of the human protein kinase CK2 a pT7-7 expression
system in Escherichia coli BL21 (DE3) was used. Newly transformed
starter cultures were grown overnight at 37 C in LB-medium to the
stationary phase. New medium was inoculated with the separate
starter cultures for both subunits and cultivated until an OD500 of
0.6 was reached. Expressionwas induced by addition of IPTG (1mM
ﬁnal concentration) and carried out at 30 C for 5e6 h for CSNK2A1
and at 37 C for 3 h for CSNK2B. Cells were harvested by centrifu-
gation (6000 g for 10 min at 4 C) and disrupted by soniﬁcation
(three times 30 s on ice). Preparations were then centrifuged to
remove the cells debris and the bacterial extracts for both subunits
were combined and puriﬁed by a three-column procedure. Frac-
tions exhibiting CK2 activity were combined and analyzed by
SDS-PAGE and Western Blot.
6.3.2. Capillary electrophoresis based assay for the testing of
inhibitors of the human CK2
The recently established capillary electrophoresis CK2 activity
assay was used for testing the inhibitors [42]. Therefore, 2 mL of the
dissolved inhibitors (stock solution in DMSO) were mixed with
78 mL of CK2 supplemented kinase buffer which was composed of
1 mg CK2 holoenzyme, 50 mM Tris/HCl (pH 7.5), 100 mM NaCl,
10 mM MgCl2 and 1 mM DTT. The reaction was initiated by the
addition of 120 mL assay buffer, whichwas composed of 25mMTris/
HCl (pH 8.5), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 100 mM ATP
and 0.19 mM of the substrate peptide RRRDDDSDDD. The reaction
was carried out for 15 min at 37 C and stopped by the addition of
4 mL EDTA (0.5 M). Subsequently the reaction mixture was analyzed
by a PA800 capillary electrophoresis from Beckman Coulter (Kre-
feld, Germany). Acetic acid (2 M, adjusted with conc. HCl to a pH of
2.0) was used as the electrolyte for electrophoretic separation. The
separated substrate and product peptide were detected at 214 nm
using a DAD-detector. Pure solvent was used as negative control (0%
inhibition), assays devoid of CK2 were used as positive control
(100% inhibition). For primary testing an inhibitor concentration of
10 mMwas used. Compounds that revealed at least 50% inhibition at
10 mMwere used for IC50 determinations. For the determination of
IC50 inhibition was determined using nine inhibitor concentrations
ranging from 0.001 mM to 100 mM. IC50 values were calculated from
the resulting doseeresponse curves.
6.3.3. Cell culture
The human leukemic cell lines U937, K562, MV-4-11 and Jurkat
were grown in RPMI 1640 medium (Life Technology, France)supplemented with 10% fetal calf serum (FCS), antibiotics (100 U/
mL penicillin, 100 mg/mL streptomycin) and L-glutamine, (Eurobio,
France) at 37 C, 5% CO2 in air. The toxicity of various molecules was
also evaluated on non-activated, freshly isolated normal human
peripheral blood mononuclear cells (PBMNC), as well as phytohe-
magglutinin (T lymphoproliferative agent) (PHA)-induced cells.
PBMNC from blood of healthy volunteers were obtained following
centrifugation on Ficoll gradient. Cells were then incubated in
medium alone or induced to enter cell cycle by the addition of PHA
(5 mg/mL, Murex Biotech Limited, Dartford, UK).
6.3.4. Cytotoxicity test
The MTS cell proliferation assay (Promega, France) is a colori-
metric assay system, which measures the reduction of a tetrazo-
lium component (MTS) into formazan produced by the
mitochondria of viable cells. Cells were washed twice in PBS
(Phosphate Buffer Saline) and plated in quadruplicate into
microtiter-plate wells in 100 mL culture media with or without our
various compounds at increasing concentrations (0, 1, 5, 10, 20 and
50 mM) during 1, 2 and 3 days. After 3 h of incubation at 37 C with
20 mL MTS/well, the plates were read by using an ELISA microplate
reader (Thermo, Electrocorporation) at 490 nm wavelength. The
amount of color produced was directly proportional to the number
of viable cells. The results are expressed as the concentrations
inhibiting cell growth by 50% after a 3 days incubation period. The
50% cytotoxic concentrations (CC50) were determined by linear
regression analysis, expressed in mM  SD (Microsoft Excel).6.4. Computational methods
The geometries of the 1f and 1c compounds were optimized
using the ab initio quantum chemistry program Gaussian 03 and
the HF/6-31G** basis set [53]. RESP (restraint electrostatic poten-
tial) atomic charges of both inhibitors were calculated to generate
the corresponding force ﬁeld parameters.
Molecular dynamics (MD) were performed by using the
AMBER12 software package [54]. The crystal structure of the CK2/
CX-4945 complex (pdb: 3pe1) [48] was used as starting structure
for the MD simulations; having removed the sulfate ions and water
molecules, except those water molecules located within 5 A of the
ligand. The CK2/1f complex was built in silico by superposing the
central ring atoms of the ligand with the corresponding atoms of
the CX-4945 compound in the CK2/CX-4945 complex. To build the
CK2/1c complex two initial orientations of the ligand were chosen:
onewith the heterocyclic system orientated as in the 1f system and
the other with the 1c A-ring sited at the position of the 1f C-ring,
and vice versa. The complexes were immersed in an octahedral box
of TIP3P water molecules using the Leap module, giving ﬁnal sys-
tems of around 45,000 atoms. The systems were initially optimized
and then gradually heated to 300 K. Starting from these equili-
brated structures 40 ns MD production runs were performed. All
simulations were carried out at 1 atm and 300 K, maintained with
the Berendsen barostat and thermostat [55], using periodic
boundary conditions and Ewald sums (grid spacing of 1 A) for
treating long range electrostatic interactions. The SHAKE algorithm
was used to keep bonds involving H atoms at their equilibrium
length, allowing the use of a 2 fs time step for the integration of
Newton’s equations. The ligand parameters were assigned with the
general AMBER force ﬁeld (GAFF) and the corresponding RESP
charges with the Antechamber module of AMBER. The Amber99
force ﬁeld parameters were used for all residues [56] excepted for
the ligands. Computed energetic contributions of 1f and 1c corre-
sponded to the electrostatic energy and Van der Waals contribu-
tions arising from bond, angle and dihedral terms in the force ﬁeld.
J. Guillon et al. / European Journal of Medicinal Chemistry 65 (2013) 205e222222Calculations were performed using the MMPBSA.py method on
500 snapshots of the last 20 ns of the trajectories.
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